Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,20159382,peak,"The objectives of the present study were to develop a novel atropine sulfate (AS) sublingual injection formulation, to create its bioavailability data in humans and to evaluate its suitability for field use with a view to obtain early therapeutic drug concentration in comparison to the conventional intramuscular route that provides a therapeutic peak of 6 to 8 ng/mL in blood at 30 minutes.",Clinical and bioavailability studies of sublingually administered atropine sulfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159382/),[ng] / [ml],6 to 8,3431,DB00572,Atropine
,20159382,Peak plasma concentration,Peak plasma concentration of AS occurred at 15 minutes and was 21 ng/mL.,Clinical and bioavailability studies of sublingually administered atropine sulfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159382/),[ng] / [ml],21,3432,DB00572,Atropine
,6468478,KD for binding,The KD for binding was 0.48 nM and Bmax was 1.42 pmol/mg protein.,Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),nM,0.48,8136,DB00572,Atropine
,6468478,Bmax,The KD for binding was 0.48 nM and Bmax was 1.42 pmol/mg protein.,Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),[pM] / [mg],1.42,8137,DB00572,Atropine
,6468478,half-life,The half-life calculated by the RRA was 3.7 +/- 2.3 h (m +/- SD) and by the RIA 4.3 +/- 1.7 h.,Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),h,3.7,8138,DB00572,Atropine
,6468478,half-life,The half-life calculated by the RRA was 3.7 +/- 2.3 h (m +/- SD) and by the RIA 4.3 +/- 1.7 h.,Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),h,4.3,8139,DB00572,Atropine
,6468478,volume of distribution,"Both the volume of distribution and the total clearance were higher according to the RRA than the RIA: 3.9 +/- 1.5 vs 1.7 +/- 0.71/kg and 15.4 +/- 10.3 vs 5.9 +/- 3.6 ml/min/kg, respectively.",Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),1/[kg],3.9,8140,DB00572,Atropine
,6468478,volume of distribution,"Both the volume of distribution and the total clearance were higher according to the RRA than the RIA: 3.9 +/- 1.5 vs 1.7 +/- 0.71/kg and 15.4 +/- 10.3 vs 5.9 +/- 3.6 ml/min/kg, respectively.",Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),1/[kg],1.7,8141,DB00572,Atropine
,6468478,total clearance,"Both the volume of distribution and the total clearance were higher according to the RRA than the RIA: 3.9 +/- 1.5 vs 1.7 +/- 0.71/kg and 15.4 +/- 10.3 vs 5.9 +/- 3.6 ml/min/kg, respectively.",Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),1/[kg],1.7,8142,DB00572,Atropine
,6468478,total clearance,"Both the volume of distribution and the total clearance were higher according to the RRA than the RIA: 3.9 +/- 1.5 vs 1.7 +/- 0.71/kg and 15.4 +/- 10.3 vs 5.9 +/- 3.6 ml/min/kg, respectively.",Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),[ml] / [kg·min],15.4,8143,DB00572,Atropine
,6468478,total clearance,"Both the volume of distribution and the total clearance were higher according to the RRA than the RIA: 3.9 +/- 1.5 vs 1.7 +/- 0.71/kg and 15.4 +/- 10.3 vs 5.9 +/- 3.6 ml/min/kg, respectively.",Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),[ml] / [kg·min],5.9,8144,DB00572,Atropine
,6468478,AUC,"The AUC measured by the RRA and RIA was 29.8 +/- 18.9 and 103.9 +/- 110.7 micrograms X h/l, respectively.",Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),[h·μg] / [l],29.8,8145,DB00572,Atropine
,6468478,AUC,"The AUC measured by the RRA and RIA was 29.8 +/- 18.9 and 103.9 +/- 110.7 micrograms X h/l, respectively.",Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468478/),[h·μg] / [l],103.9,8146,DB00572,Atropine
,24748278,maximum drug plasma concentrations (C max),"After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 ± 53.66, 267.50 ± 33.16, 340.50 ± 44.52, and 483.75 ± 78.13 ng/mL.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],274.25,9682,DB00572,Atropine
,24748278,maximum drug plasma concentrations (C max),"After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 ± 53.66, 267.50 ± 33.16, 340.50 ± 44.52, and 483.75 ± 78.13 ng/mL.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],267.50,9683,DB00572,Atropine
,24748278,maximum drug plasma concentrations (C max),"After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 ± 53.66, 267.50 ± 33.16, 340.50 ± 44.52, and 483.75 ± 78.13 ng/mL.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],340.50,9684,DB00572,Atropine
,24748278,maximum drug plasma concentrations (C max),"After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 ± 53.66, 267.50 ± 33.16, 340.50 ± 44.52, and 483.75 ± 78.13 ng/mL.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],483.75,9685,DB00572,Atropine
,24748278,bioavailability,"Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,21.62,9686,DB00572,Atropine
,24748278,bioavailability,"Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,10.78,9687,DB00572,Atropine
,24748278,bioavailability,"Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,80.45,9688,DB00572,Atropine
,24748278,bioavailability,"Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,2.52,9689,DB00572,Atropine
below,24748278,C max,"Following i.g. administration of tiotropium, the C max value below 20 ng/mL revealed the very low oral absorption.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],20,9690,DB00572,Atropine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,11.33,9691,DB00572,Atropine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,54.86,9692,DB00572,Atropine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,32.67,9693,DB00572,Atropine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,8.69,9694,DB00572,Atropine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,73.91,9695,DB00572,Atropine
,21771644,Elimination half-life,"Elimination half-life of S-hyoscyamine was 1.5 h, showing occasionally a second slow elimination phase with t(½)=12 h.",Atropine maintenance dosage in patients with severe organophosphate pesticide poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771644/),h,1.5,10812,DB00572,Atropine
,21771644,t(½),"Elimination half-life of S-hyoscyamine was 1.5 h, showing occasionally a second slow elimination phase with t(½)=12 h.",Atropine maintenance dosage in patients with severe organophosphate pesticide poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771644/),h,12,10813,DB00572,Atropine
,11920923,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 991 and 839 ng x ml(-1) for seizure terminated and not terminated, respectively.",Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],991,13442,DB00572,Atropine
,11920923,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 991 and 839 ng x ml(-1) for seizure terminated and not terminated, respectively.",Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],839,13443,DB00572,Atropine
,11920923,plasma Cmax,The plasma Cmax in seizure-terminated animals in this study is similar to the minimum range of plasma diazepam (200-800 ng x ml(-1)) reported to suppress seizure activity in humans.,Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],200-800,13444,DB00572,Atropine
,11920923,Cmax,It has been reported in an earlier study that the minimum effective i.m. dose (0.1 mg x kg(-1)) required to prevent soman-induced convulsions in Rhesus monkeys produces a mean Cmax of 50 ng x ml(-1) for diazepam.,Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],50,13445,DB00572,Atropine
,2328309,t1/2,"The control t1/2, CL and Vd of HI-offere 27 min, 8.6 ml min-1 kg-1 and 0.34 l kg-1, respectively.","Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),min,27,16343,DB00572,Atropine
,2328309,CL,"The control t1/2, CL and Vd of HI-offere 27 min, 8.6 ml min-1 kg-1 and 0.34 l kg-1, respectively.","Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),[ml] / [kg·min],8.6,16344,DB00572,Atropine
,2328309,Vd,"The control t1/2, CL and Vd of HI-offere 27 min, 8.6 ml min-1 kg-1 and 0.34 l kg-1, respectively.","Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),[l] / [kg],0.34,16345,DB00572,Atropine
,2328309,t1/2,Methoxyflurane anesthesia resulted in a significant increase in the HI-6 t1/2 to 61 min concomitant with a decrease in the CL to 4.1 ml min-1 kg-1 with no change in the Vd.,"Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),min,61,16346,DB00572,Atropine
,2328309,CL,Methoxyflurane anesthesia resulted in a significant increase in the HI-6 t1/2 to 61 min concomitant with a decrease in the CL to 4.1 ml min-1 kg-1 with no change in the Vd.,"Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),[ml] / [kg·min],4.1,16347,DB00572,Atropine
,4036539,maximum serum concentration,"Following p.o. administration of atropine, the mean maximum serum concentration of 6.7 nmol/l occurred at 2 h.",Comparison of pharmacokinetic and pharmacodynamic parameters following oral or intramuscular atropine in children. Atropine overdose in two small children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4036539/),[nM] / [l],6.7,17603,DB00572,Atropine
,4036539,Ser,"Serum concentrations of atropine were 3.5 and 1.3 nmol/l 8 h after p.o. and i.m. administration, respectively.",Comparison of pharmacokinetic and pharmacodynamic parameters following oral or intramuscular atropine in children. Atropine overdose in two small children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4036539/),,3.5,17604,DB00572,Atropine
,4036539,Ser,"Serum concentrations of atropine were 3.5 and 1.3 nmol/l 8 h after p.o. and i.m. administration, respectively.",Comparison of pharmacokinetic and pharmacodynamic parameters following oral or intramuscular atropine in children. Atropine overdose in two small children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4036539/),,1.3,17605,DB00572,Atropine
,4036539,maximum rise,The mean maximum rise in the rectal temperature before the start of anaesthesia occurred at 1 h and was 0.5 degrees C in the p.o. group and 0.7 degrees C in the i.m. group.,Comparison of pharmacokinetic and pharmacodynamic parameters following oral or intramuscular atropine in children. Atropine overdose in two small children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4036539/),degrees,0.5,17606,DB00572,Atropine
,4036539,maximum rise,The mean maximum rise in the rectal temperature before the start of anaesthesia occurred at 1 h and was 0.5 degrees C in the p.o. group and 0.7 degrees C in the i.m. group.,Comparison of pharmacokinetic and pharmacodynamic parameters following oral or intramuscular atropine in children. Atropine overdose in two small children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4036539/),c·degrees,0.7,17607,DB00572,Atropine
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],320,17617,DB00572,Atropine
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],290,17618,DB00572,Atropine
,10873073,terminal phase half-life,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),h,12.4,17619,DB00572,Atropine
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17620,DB00572,Atropine
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],234,17621,DB00572,Atropine
,10873073,terminal phase volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17622,DB00572,Atropine
,10873073,steady-state volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],123,17623,DB00572,Atropine
,28941624,plasma t1/2,PK analysis revealed a rapid distribution of the oxime with a plasma t1/2 of ∼1 h.,The biodistribution and pharmacokinetics of the oxime acetylcholinesterase reactivator RS194B in guinea pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28941624/),h,∼1,18575,DB00572,Atropine
,28941624,brain-to-plasma ratio,"The Cmax in the brain ranged between 0.03 and 0.18% of the administered dose, and the brain-to-plasma ratio ranged from 0.04 at the 10 mg/kg dose to 0.18 at the 200 mg/kg dose demonstrating dose dependent differences in brain and plasma concentrations.",The biodistribution and pharmacokinetics of the oxime acetylcholinesterase reactivator RS194B in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28941624/),,0.04,18576,DB00572,Atropine
,28941624,brain-to-plasma ratio,"The Cmax in the brain ranged between 0.03 and 0.18% of the administered dose, and the brain-to-plasma ratio ranged from 0.04 at the 10 mg/kg dose to 0.18 at the 200 mg/kg dose demonstrating dose dependent differences in brain and plasma concentrations.",The biodistribution and pharmacokinetics of the oxime acetylcholinesterase reactivator RS194B in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28941624/),,0.18,18577,DB00572,Atropine
,10217331,EC50,"Mean (+/-SD) EC50, sigmoidicity factor (gamma), and equilibration rate constant (k(e0)) estimates were 1.35 (+/-0.27) ng/mL, 6.07 (+/-1.98) and 11.0 (+/-5.28) l/h for atropine and 1.35 (+/-0.49) ng/mL, 4.34 (+/-1.55) and 2.26 (+/-0.81) l/h for glycopyrrolate.",Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217331/),[ng] / [ml],1.35,21557,DB00572,Atropine
,10217331,rate constant (k(e0)),"Mean (+/-SD) EC50, sigmoidicity factor (gamma), and equilibration rate constant (k(e0)) estimates were 1.35 (+/-0.27) ng/mL, 6.07 (+/-1.98) and 11.0 (+/-5.28) l/h for atropine and 1.35 (+/-0.49) ng/mL, 4.34 (+/-1.55) and 2.26 (+/-0.81) l/h for glycopyrrolate.",Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217331/),[l] / [h],11.0,21558,DB00572,Atropine
,10582751,heart rate,Mean heart rate of all dogs varied from 52 to 140 beats/min during the infusion.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[beats] / [min],52 to 140,28977,DB00572,Atropine
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,26,28978,DB00572,Atropine
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,30,28979,DB00572,Atropine
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,59,28980,DB00572,Atropine
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,105,28981,DB00572,Atropine
,10582751,Mean residence time (MRTinf),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,104.7,28982,DB00572,Atropine
,10582751,body clearance (Clb),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ml] / [kg·min],53.35,28983,DB00572,Atropine
,10582751,volume of distribution at steady state (Vdss),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[l] / [kg],3.27,28984,DB00572,Atropine
,10582751,Plasma concentration,Plasma concentration of fentanyl for seven dogs during the infusion varied from 1.22 to 4.54 ng/mL.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ng] / [ml],1.22 to 4.54,28985,DB00572,Atropine
,10582751,MRTinf,MRTinf for fentanyl was 111.3 +/- 5.7 minutes.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,111.3,28986,DB00572,Atropine
,10582751,body clearance,Mean body clearance was 29.1 +/- 2.2 mL/kg/min and Vdss was 2.21 +/- 0.19 L/kg.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ml] / [kg·min],29.1,28987,DB00572,Atropine
,10582751,Vdss,Mean body clearance was 29.1 +/- 2.2 mL/kg/min and Vdss was 2.21 +/- 0.19 L/kg.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[l] / [kg],2.21,28988,DB00572,Atropine
,427002,Plasma half time,Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),h,2.9,30762,DB00572,Atropine
,427002,bioavailability,Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),%,53,30763,DB00572,Atropine
,427002,Plasma protein binding,Plasma protein binding was 38% and was independent of plasma concentration; the drug was not concentrated in the red cell.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),%,38,30764,DB00572,Atropine
,3660415,minimum detectable concentration,"By integration of a thermodesorption/cold trap injector into our GLC analysis, the soman stereoisomers could be followed in rat blood down to a minimum detectable concentration, i.e., 1.5 pg/ml (8.3 pM), 55-fold lower than that published previously.",Toxicokinetics of the four stereoisomers of the nerve agent soman in atropinized rats--influence of a soman simulator. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3660415/),[pg] / [ml],1.5,34455,DB00572,Atropine
,3660415,minimum detectable concentration,"By integration of a thermodesorption/cold trap injector into our GLC analysis, the soman stereoisomers could be followed in rat blood down to a minimum detectable concentration, i.e., 1.5 pg/ml (8.3 pM), 55-fold lower than that published previously.",Toxicokinetics of the four stereoisomers of the nerve agent soman in atropinized rats--influence of a soman simulator. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3660415/),pM,8.3,34456,DB00572,Atropine
,3660415,biological half-life,"Whereas C(+)P(+)-soman disappears in vivo from rat blood within 0.25 min, the toxicokinetics of C(-)P(+)-soman could be described by a two-compartment model, with a biological half-life of 1-1.5 min.",Toxicokinetics of the four stereoisomers of the nerve agent soman in atropinized rats--influence of a soman simulator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3660415/),min,1-1.5,34457,DB00572,Atropine
,3660415,terminal half-lives,"The toxicokinetics of the P(-)-isomers are best described with a three-compartment model, with terminal half-lives of 40-64 and 16-22 min at doses of 6 and 3 LD50, respectively.",Toxicokinetics of the four stereoisomers of the nerve agent soman in atropinized rats--influence of a soman simulator. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3660415/),min,40-64,34458,DB00572,Atropine
,3660415,terminal half-lives,"The toxicokinetics of the P(-)-isomers are best described with a three-compartment model, with terminal half-lives of 40-64 and 16-22 min at doses of 6 and 3 LD50, respectively.",Toxicokinetics of the four stereoisomers of the nerve agent soman in atropinized rats--influence of a soman simulator. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3660415/),min,16-22,34459,DB00572,Atropine
,7324829,ta1/2,The maternal pharmacokinetics of i.v. atropine obeyed and two-compartment open model with a fast distribution phase (mean ta1/2=1.02 min) and quite fast elimination (t1/2=2.56h).,Placental transfer and pharmacokinetics of atropine after a single maternal intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324829/),min,1.02,40376,DB00572,Atropine
,7324829,t1/2,The maternal pharmacokinetics of i.v. atropine obeyed and two-compartment open model with a fast distribution phase (mean ta1/2=1.02 min) and quite fast elimination (t1/2=2.56h).,Placental transfer and pharmacokinetics of atropine after a single maternal intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324829/),h,2.56,40377,DB00572,Atropine
,7324829,total apparent volume of distribution,The total apparent volume of distribution was 1.01/kg and the total plasma clearance 6.36 ml/min/kg.,Placental transfer and pharmacokinetics of atropine after a single maternal intravenous and intramuscular administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324829/),1/[kg],1.01,40378,DB00572,Atropine
,7324829,total plasma clearance,The total apparent volume of distribution was 1.01/kg and the total plasma clearance 6.36 ml/min/kg.,Placental transfer and pharmacokinetics of atropine after a single maternal intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324829/),[ml] / [kg·min],6.36,40379,DB00572,Atropine
,7324829,half-life of elimination,The mean peak maternal plasma levels after i.m. atropine administration were found at 1.59 h and the mean calculated half-life of elimination was then 2.1 h.,Placental transfer and pharmacokinetics of atropine after a single maternal intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324829/),h,2.1,40380,DB00572,Atropine
,2503375,clearance,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[ml] / [kg·min],5.2,41034,DB00572,Atropine
,2503375,volume of distribution,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[1] / [kg],0.63,41035,DB00572,Atropine
,2503375,elimination half-life,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),min,96.9,41036,DB00572,Atropine
,4082877,peak plasma concentration,The mean peak plasma concentration of atropine was 1.17 ng/ml and it was reached after 33 min.,The influence of body weight on plasma concentration of atropine after rectal administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4082877/),[ng] / [ml],1.17,42193,DB00572,Atropine
,4082877,peak plasma concentration,"In the group of smaller children (b.w. less than 15 kg) the peak plasma concentration was (0.83 ng/ml) lower than that observed in older children (1.26-1.36 ng/ml), but this difference was not statistically significant.",The influence of body weight on plasma concentration of atropine after rectal administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4082877/),[ng] / [ml],0.83,42194,DB00572,Atropine
,4082877,peak plasma concentration,"In the group of smaller children (b.w. less than 15 kg) the peak plasma concentration was (0.83 ng/ml) lower than that observed in older children (1.26-1.36 ng/ml), but this difference was not statistically significant.",The influence of body weight on plasma concentration of atropine after rectal administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4082877/),[ng] / [ml],1.26-1.36,42195,DB00572,Atropine
,25044356,maximum concentrations,"The maximum concentration of these three tropane alkaloids was reached within 15 min, and the maximum concentrations were 31.36 ± 7.35 ng/mL for atropine, 49.94 ± 2.67 ng/mL for scopolamine, and 2.83 ± 1.49 ng/mL for anisodamine.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [ml],31.36,42316,DB00572,Atropine
,25044356,maximum concentrations,"The maximum concentration of these three tropane alkaloids was reached within 15 min, and the maximum concentrations were 31.36 ± 7.35 ng/mL for atropine, 49.94 ± 2.67 ng/mL for scopolamine, and 2.83 ± 1.49 ng/mL for anisodamine.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [ml],49.94,42317,DB00572,Atropine
,25044356,maximum concentrations,"The maximum concentration of these three tropane alkaloids was reached within 15 min, and the maximum concentrations were 31.36 ± 7.35 ng/mL for atropine, 49.94 ± 2.67 ng/mL for scopolamine, and 2.83 ± 1.49 ng/mL for anisodamine.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [ml],2.83,42318,DB00572,Atropine
,25044356,areas under the curve,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [h·ml],22.76,42319,DB00572,Atropine
,25044356,areas under the curve,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [h·ml],16.80,42320,DB00572,Atropine
,25044356,areas under the curve,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [h·ml],4.31,42321,DB00572,Atropine
,25044356,mean residence times,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),h,2.08,42322,DB00572,Atropine
,25044356,mean residence times,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),h,1.19,42323,DB00572,Atropine
,25044356,mean residence times,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),h,3.28,42324,DB00572,Atropine
,6337802,peak serum concentration,Amiodarone is incompletely (approximately 50 percent) and slowly (peak serum concentration approximately 6 h) absorbed.,"Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),h,6,47537,DB00572,Atropine
,6337802,apparent elimination half-life,"It has an apparent elimination half-life of 15-45 days, which presents unique dosing problems.","Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),d,15-45,47538,DB00572,Atropine
,6337802,apparent therapeutic range,The apparent therapeutic range is 0.6-3 microgram/ml.,"Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),[μg] / [ml],0.6-3,47539,DB00572,Atropine
,1294333,gastric emptying time,"Here, the gastric acidity, the gastric emptying time and the small intestinal transit time in the regulated-dogs were respectively around pH 2, 0.7h and 4h, approximating those in healthy humans.",Bioavailability study of commercial sustained-release preparations of diclofenac sodium in gastrointestinal physiology regulated-dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1294333/),h,0.7,48203,DB00572,Atropine
,1294333,small intestinal transit time,"Here, the gastric acidity, the gastric emptying time and the small intestinal transit time in the regulated-dogs were respectively around pH 2, 0.7h and 4h, approximating those in healthy humans.",Bioavailability study of commercial sustained-release preparations of diclofenac sodium in gastrointestinal physiology regulated-dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1294333/),h,4,48204,DB00572,Atropine
,11878186,pKi,Receptor binding studies on the cloned human muscarinic receptors indicated that the new soft anticholinergic agents possessed moderate potency as pKi ranged from 6.7 to 7.6.,"Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopentylacetate. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878186/),,6.7,50908,DB00572,Atropine
,11878186,pKi,Receptor binding studies on the cloned human muscarinic receptors indicated that the new soft anticholinergic agents possessed moderate potency as pKi ranged from 6.7 to 7.6.,"Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopentylacetate. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878186/),,7.6,50909,DB00572,Atropine
,11878186,duration of,"Mydriatic studies in rabbit eyes revealed that the duration of the action of the new soft anticholinergics (8.5-11.0 h) were shorter than that of atropine (about 24 h) under pharmacodynamic equivalent dose, and one of them, 18a, showed even shorter than that of tropicamide.","Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopentylacetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878186/),h,8.5-11.0,50910,DB00572,Atropine
,11878186,duration of,"Mydriatic studies in rabbit eyes revealed that the duration of the action of the new soft anticholinergics (8.5-11.0 h) were shorter than that of atropine (about 24 h) under pharmacodynamic equivalent dose, and one of them, 18a, showed even shorter than that of tropicamide.","Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopentylacetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878186/),h,24,50911,DB00572,Atropine
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[ng] / [l],70,54218,DB00572,Atropine
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[μg] / [l],2,54219,DB00572,Atropine
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[ng] / [l],140,54220,DB00572,Atropine
,2077523,maximum plasma concentration (Cmax),A very rapid absorption was found with a mean maximum plasma concentration (Cmax) of 14.26 (range 12.02-16.97) micrograms/l and mean Tmax (time to Cmax) of 13.3 (range 10-15) min. and almost 50% of the dose administered was excreted into the urine within 3 hr.,Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[μg] / [l],14.26,54221,DB00572,Atropine
,2077523,Tmax (time to Cmax),A very rapid absorption was found with a mean maximum plasma concentration (Cmax) of 14.26 (range 12.02-16.97) micrograms/l and mean Tmax (time to Cmax) of 13.3 (range 10-15) min. and almost 50% of the dose administered was excreted into the urine within 3 hr.,Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),min,13.3,54222,DB00572,Atropine
,10321537,area under the curve from zero to infinitum (AUC0-infinity),"The mean area under the curve from zero to infinitum (AUC0-infinity) for 1-hyoscyamine was 1.862+/-0.580 microg/L x hr after intravenous, and 1.092+/-0.381 microl/L x hr after ocular administration (mean+/-sd, n=6), respectively.",Systemic bioavailability of ocularly applied 1% atropine eyedrops. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321537/),[μg] / [h·l],1.862,62557,DB00572,Atropine
,10321537,area under the curve from zero to infinitum (AUC0-infinity),"The mean area under the curve from zero to infinitum (AUC0-infinity) for 1-hyoscyamine was 1.862+/-0.580 microg/L x hr after intravenous, and 1.092+/-0.381 microl/L x hr after ocular administration (mean+/-sd, n=6), respectively.",Systemic bioavailability of ocularly applied 1% atropine eyedrops. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321537/),[μl] / [h·l],1.092,62558,DB00572,Atropine
,10321537,bioavailability,"The mean bioavailability was 63.5+/-28.6% (mean+/-SD, n=6; min 19%, max 95%).",Systemic bioavailability of ocularly applied 1% atropine eyedrops. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321537/),%,63.5,62559,DB00572,Atropine
,10321537,max,"The mean bioavailability was 63.5+/-28.6% (mean+/-SD, n=6; min 19%, max 95%).",Systemic bioavailability of ocularly applied 1% atropine eyedrops. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321537/),%,95,62560,DB00572,Atropine
,2972054,peak plasma concentrations,"Ipratropium bromide absorbed fast, and peak plasma concentrations of the drug (257 +/- 55 pg/ml) were detected as soon as 5 min after the last inhalation (at 35 min from the beginning).",Evaluation of the systemic anticholinergic activity of nasally administered ipratropium bromide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2972054/),[pg] / [ml],257,63951,DB00572,Atropine
,4032240,apparent half-lives,Two phases with apparent half-lives of 1 and 140 min were distinguishable in accordance with a linear two-compartment disposition model for atropine.,Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. I: Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032240/),min,1,65852,DB00572,Atropine
,4032240,apparent half-lives,Two phases with apparent half-lives of 1 and 140 min were distinguishable in accordance with a linear two-compartment disposition model for atropine.,Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. I: Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032240/),min,140,65853,DB00572,Atropine
,4032240,urinary excretion,The urinary excretion of unchanged drug was 57% of the dose.,Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. I: Pharmacokinetics. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032240/),%,57,65854,DB00572,Atropine
,4032240,steady-state volume of distribution,"The steady-state volume of distribution was 210 L, implying extensive tissue binding and/or partitioning.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. I: Pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032240/),l,210,65855,DB00572,Atropine
,4032240,Renal plasma clearance,"Renal plasma clearance was 660 mL/min, suggesting significant tubular secretion.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. I: Pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032240/),[ml] / [min],660,65856,DB00572,Atropine
,9298924,LD50,"Pharmacokinetic parameters of unbound HI 6 in blood and brain were calculated after administration of HI 6 (50, 75 or 100 mg/kg i.m.) in control rats and rats injected with soman (90 microg/kg s.c., 0.9 LD50) 1 min before HI 6 treatment.",Pharmacokinetics and effects of HI 6 in blood and brain of soman-intoxicated rats: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9298924/),,0.,65944,DB00572,Atropine
,2076724,volume of distribution (Vz,"Ex prior to atropine (T2) significantly decreased the mean volume of distribution (Vz, 278 vs 232 l).",The effect of exercise on atropine pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),l,278,66853,DB00572,Atropine
,2076724,volume of distribution (Vz,"Ex prior to atropine (T2) significantly decreased the mean volume of distribution (Vz, 278 vs 232 l).",The effect of exercise on atropine pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),l,232,66854,DB00572,Atropine
,2076724,serum half life (t1/2,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),h,4.2,66855,DB00572,Atropine
,2076724,serum half life (t1/2,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),h,3.5,66856,DB00572,Atropine
,2076724,Vz,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),l,278,66857,DB00572,Atropine
,2076724,Vz,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),l,198,66858,DB00572,Atropine
,2076724,clearance (CL,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[ml] / [min],763,66859,DB00572,Atropine
,2076724,clearance (CL,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[ml] / [min],638,66860,DB00572,Atropine
,2076724,peak concentration (Cp,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[ng] / [ml],6.7,66861,DB00572,Atropine
,2076724,peak concentration (Cp,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[ng] / [ml],12.3,66862,DB00572,Atropine
,2076724,area under the curve (AUC,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[ng] / [ml],44.1,66863,DB00572,Atropine
,2076724,area under the curve (AUC,"Ex in T3 significantly decreased the serum half life (t1/2, 4.2 vs 3.5 h), Vz (278 vs 198 l), and clearance (CL, 763 vs 638 ml.min-1) and significantly increased the peak concentration (Cp, 6.7 vs 12.3 ng.ml-1) and area under the curve (AUC, 44.1 vs 53.1 ng.ml-1).",The effect of exercise on atropine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[ng] / [ml],53.1,66864,DB00572,Atropine
,2076724,t1/2,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),h,3.4,66865,DB00572,Atropine
,2076724,Vz,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),l,182,66866,DB00572,Atropine
,2076724,CL,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[ml] / [min],575,66867,DB00572,Atropine
,2076724,absorption rate constant (ka,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),1/[min],0.482,66868,DB00572,Atropine
,2076724,absorption rate constant (ka,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),1/[min],1.1,66869,DB00572,Atropine
,2076724,elimination rate constant (ke,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),1/[min],0.0012,66870,DB00572,Atropine
,2076724,elimination rate constant (ke,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),1/[min],0.0015,66871,DB00572,Atropine
,2076724,Cp,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[ng] / [ml],14,66872,DB00572,Atropine
,2076724,AUC,"In T5, Ex significantly decreased the t1/2 (3.4 h), Vz (182 l) and CL (575 ml.min-1) and significantly increased the absorption rate constant (ka, 0.482 vs 1.1 min-1), elimination rate constant (ke, 0.0012 vs 0.0015 min-1), Cp (14 ng.ml-1) and AUC (53.3 ng.h.ml-1).",The effect of exercise on atropine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076724/),[h·ng] / [ml],53.3,66873,DB00572,Atropine
,16479380,t(1/2alpha),In the case of parathion-ethyl the distribution half-life estimated was t(1/2alpha) = 3.1h while the terminal half-life was t(1/2beta) = 17.9 h.,Organophosphate poisonings with parathion and dimethoate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16479380/),h,3.1,70656,DB00572,Atropine
,16479380,terminal half-life was t(1/2beta),In the case of parathion-ethyl the distribution half-life estimated was t(1/2alpha) = 3.1h while the terminal half-life was t(1/2beta) = 17.9 h.,Organophosphate poisonings with parathion and dimethoate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16479380/),h,17.9,70657,DB00572,Atropine
,16479380,t(1/2beta),Using a one-compartment model for dimethoate the elimination half-life was t(1/2beta) = 30.4 h in plasma and 23.8 h in urine.,Organophosphate poisonings with parathion and dimethoate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16479380/),h,30.4,70658,DB00572,Atropine
,16479380,t(1/2beta),Using a one-compartment model for dimethoate the elimination half-life was t(1/2beta) = 30.4 h in plasma and 23.8 h in urine.,Organophosphate poisonings with parathion and dimethoate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16479380/),h,23.8,70659,DB00572,Atropine
,8868291,distribution half-lives,"Both radioligands were cleared from the circulation with distribution half-lives of 17 and 14 sec and elimination half-lives of 17 and 40 min for [3H]AF-DX 116 and [3H]AF-DX 384, respectively.","In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868291/),s,17,72789,DB00572,Atropine
,8868291,distribution half-lives,"Both radioligands were cleared from the circulation with distribution half-lives of 17 and 14 sec and elimination half-lives of 17 and 40 min for [3H]AF-DX 116 and [3H]AF-DX 384, respectively.","In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868291/),s,14,72790,DB00572,Atropine
,8868291,elimination half-lives,"Both radioligands were cleared from the circulation with distribution half-lives of 17 and 14 sec and elimination half-lives of 17 and 40 min for [3H]AF-DX 116 and [3H]AF-DX 384, respectively.","In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868291/),min,17,72791,DB00572,Atropine
,8868291,elimination half-lives,"Both radioligands were cleared from the circulation with distribution half-lives of 17 and 14 sec and elimination half-lives of 17 and 40 min for [3H]AF-DX 116 and [3H]AF-DX 384, respectively.","In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868291/),min,40,72792,DB00572,Atropine
,14620526,pKi,Receptor binding studies of the soft anticholinergics on cloned muscarinic receptors indicated pKi values in the range of 7.5 to 8.9.,"Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620526/),,7.5 to 8.9,73399,DB00572,Atropine
,468451,recoveries,The 24 hr recoveries in urine were 8--13% for furagin and about 36% for nitrofurantoin.,"Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/468451/),%,8--,74381,DB00572,Atropine
,468451,recoveries,The 24 hr recoveries in urine were 8--13% for furagin and about 36% for nitrofurantoin.,"Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/468451/),%,13,74382,DB00572,Atropine
,468451,recoveries,The 24 hr recoveries in urine were 8--13% for furagin and about 36% for nitrofurantoin.,"Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/468451/),%,36,74383,DB00572,Atropine
,15198070,time to seizure termination,The mean time to seizure termination was 8.8 +/- 1.6 min.,Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,8.8,74668,DB00572,Atropine
,15198070,apparent volumes of distribution (Vd),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[l] / [kg],1.4,74669,DB00572,Atropine
,15198070,apparent volumes of distribution (Vd),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[l] / [kg],1.7,74670,DB00572,Atropine
,15198070,area under the time-concentration curves (AUC),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[min·ng] / [ml],"15,990",74671,DB00572,Atropine
,15198070,area under the time-concentration curves (AUC),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[min·ng] / [ml],"15,120",74672,DB00572,Atropine
,15198070,times to maximal plasma concentration (Tmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,1.66,74673,DB00572,Atropine
,15198070,times to maximal plasma concentration (Tmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,2.91,74674,DB00572,Atropine
,15198070,maximal plasma concentrations (Cmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[ng] / [ml],535.1,74675,DB00572,Atropine
,15198070,maximal plasma concentrations (Cmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[ng] / [ml],436.6,74676,DB00572,Atropine
,15362593,Cmax,"After the acetaminophen ingestion, median Cmax occurred at 1 h for all three exposures but was lower in the atropine-treated study arm (31+/-19 mg/L) than in the control or charcoal alone intervention arms (49+/-13 and 51+/-16 mg/L, respectively) (P<0.05).",Effect of anticholinergic drugs on the efficacy of activated charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15362593/),[mg] / [l],31,79313,DB00572,Atropine
,15362593,Cmax,"After the acetaminophen ingestion, median Cmax occurred at 1 h for all three exposures but was lower in the atropine-treated study arm (31+/-19 mg/L) than in the control or charcoal alone intervention arms (49+/-13 and 51+/-16 mg/L, respectively) (P<0.05).",Effect of anticholinergic drugs on the efficacy of activated charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15362593/),[mg] / [l],49,79314,DB00572,Atropine
,15362593,Cmax,"After the acetaminophen ingestion, median Cmax occurred at 1 h for all three exposures but was lower in the atropine-treated study arm (31+/-19 mg/L) than in the control or charcoal alone intervention arms (49+/-13 and 51+/-16 mg/L, respectively) (P<0.05).",Effect of anticholinergic drugs on the efficacy of activated charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15362593/),[mg] / [l],51,79315,DB00572,Atropine
,7337075,pKa,Prepharmacokinetic studies determined pKa values for atropine and tropine of 9.56 and 10.35 respectively at 22 degrees C.,Atropine: a sensitive gas chromatography-mass spectrometry assay and prepharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337075/),,9.56,80400,DB00572,Atropine
,7337075,pKa,Prepharmacokinetic studies determined pKa values for atropine and tropine of 9.56 and 10.35 respectively at 22 degrees C.,Atropine: a sensitive gas chromatography-mass spectrometry assay and prepharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337075/),,10.35,80401,DB00572,Atropine
,1585397,peak concentrations,"Mean peak concentrations were 4.9, 6.1, and 7.9 ng/ml for the inhaled doses and 8.4 ng/ml for the i.m. dose.",Comparative absorption of atropine from a metered-dose inhaler and an intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585397/),[ng] / [ml],4.9,81302,DB00572,Atropine
,1585397,peak concentrations,"Mean peak concentrations were 4.9, 6.1, and 7.9 ng/ml for the inhaled doses and 8.4 ng/ml for the i.m. dose.",Comparative absorption of atropine from a metered-dose inhaler and an intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585397/),[ng] / [ml],6.1,81303,DB00572,Atropine
,1585397,peak concentrations,"Mean peak concentrations were 4.9, 6.1, and 7.9 ng/ml for the inhaled doses and 8.4 ng/ml for the i.m. dose.",Comparative absorption of atropine from a metered-dose inhaler and an intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585397/),[ng] / [ml],7.9,81304,DB00572,Atropine
,1585397,peak concentrations,"Mean peak concentrations were 4.9, 6.1, and 7.9 ng/ml for the inhaled doses and 8.4 ng/ml for the i.m. dose.",Comparative absorption of atropine from a metered-dose inhaler and an intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585397/),[ng] / [ml],8.4,81305,DB00572,Atropine
,18507656,heart rate,Fingolimod administration alone yielded a heart rate nadir of 51 +/- 5 beats min(-1) at a median 4 h postdose with heart rate remaining depressed at 51-64 beats min(-1) over the rest of the day.,The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18507656/),[beats] / [min],51,87953,DB00572,Atropine
,18507656,heart rate,"When atropine was administered at the time of the nadir, it was able to reverse the negative chronotropic effect of fingolimod from a heart rate of 56 +/- 9 beats min(-1) (placebo) to 64 +/- 8 beats min(-1) (atropine) resulting in an atropine: placebo ratio of 1.15 (1.04, 1.26).",The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18507656/),[beats] / [min],56,87954,DB00572,Atropine
,18507656,heart rate,"When atropine was administered at the time of the nadir, it was able to reverse the negative chronotropic effect of fingolimod from a heart rate of 56 +/- 9 beats min(-1) (placebo) to 64 +/- 8 beats min(-1) (atropine) resulting in an atropine: placebo ratio of 1.15 (1.04, 1.26).",The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18507656/),[beats] / [min],64,87955,DB00572,Atropine
,8527690,time to maximum plasma HI-6 concentration (tmax,"The mean +/- SD time to maximum plasma HI-6 concentration (tmax = 0.69 +/- 0.21 h, n = 16), and absorption half-life (t/2a = 0.17 +/- 0.05 h) indicated rapid onset of effect.",The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527690/),h,0.69,88166,DB00572,Atropine
,8527690,absorption half-life (t/2a,"The mean +/- SD time to maximum plasma HI-6 concentration (tmax = 0.69 +/- 0.21 h, n = 16), and absorption half-life (t/2a = 0.17 +/- 0.05 h) indicated rapid onset of effect.",The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527690/),h,0.17,88167,DB00572,Atropine
,8527690,volume of distribution (Vd,The volume of distribution (Vd = 0.25 +/- 0.04 L kg-1 TBW) approximated the extracellular fluid volume.,The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527690/),[l] / [kg],0.25,88168,DB00572,Atropine
,8527690,total body clearance (CL,A high total body clearance (CL = 252 +/- 52 mL min-1) and short apparent elimination half-life (t/2e = 1.15 +/- 0.19 h) were expected for this polar quaternary ammonium drug.,The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527690/),[ml] / [min],252,88169,DB00572,Atropine
,8527690,apparent elimination half-life (t/2e,A high total body clearance (CL = 252 +/- 52 mL min-1) and short apparent elimination half-life (t/2e = 1.15 +/- 0.19 h) were expected for this polar quaternary ammonium drug.,The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527690/),h,1.15,88170,DB00572,Atropine
,8527690,renal clearance CLr,"The renal clearance CLr = 137 +/- 33 mL min-1), which approximated the expected glomerular filtration rate, and 24 h urinary excretion of unchanged drug (55 +/- 10%) indicated substantial non-renal elimination.",The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527690/),[ml] / [min],137,88171,DB00572,Atropine
,8527690,urinary excretion of unchanged drug,"The renal clearance CLr = 137 +/- 33 mL min-1), which approximated the expected glomerular filtration rate, and 24 h urinary excretion of unchanged drug (55 +/- 10%) indicated substantial non-renal elimination.",The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527690/),%,55,88172,DB00572,Atropine
,14561847,half-life,"Methylecgonidine clears quickly from blood with a half-life of 18 to 21 min, whereas ecgonidine has a longer half-life of 94 to 137 min.","Pharmacokinetics and pharmacodynamics of methylecgonidine, a crack cocaine pyrolyzate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561847/),min,18 to 21,88463,DB00572,Atropine
,14561847,half-life,"Methylecgonidine clears quickly from blood with a half-life of 18 to 21 min, whereas ecgonidine has a longer half-life of 94 to 137 min.","Pharmacokinetics and pharmacodynamics of methylecgonidine, a crack cocaine pyrolyzate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561847/),min,94 to 137,88464,DB00572,Atropine
,26325216,plasma Cmax,"Following administration of 10mgkg(-1) (i.m.), MB327 DMS reached plasma Cmax of 22μM at 12min with an elimination t1/2 of 22min.",Pharmacokinetic profile and quantitation of protection against soman poisoning by the antinicotinic compound MB327 in the guinea-pig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325216/),μM,22,88616,DB00572,Atropine
,26325216,elimination t1/2,"Following administration of 10mgkg(-1) (i.m.), MB327 DMS reached plasma Cmax of 22μM at 12min with an elimination t1/2 of 22min.",Pharmacokinetic profile and quantitation of protection against soman poisoning by the antinicotinic compound MB327 in the guinea-pig. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325216/),min,22,88617,DB00572,Atropine
,26065362,time of ingestion,Aldicarb concentration at admission was 2.18 μg/ml and concentration-time data best fitted a two compartmental model with first order absorption and a time of ingestion 4.5 h preadmission.,The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),h,4.5,88859,DB00572,Atropine
,26065362,half-life of distribution,"The half-life of distribution was 0.4 h and half-life of elimination, 13 h.",The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),h,0.4,88860,DB00572,Atropine
,26065362,half-life of elimination,"The half-life of distribution was 0.4 h and half-life of elimination, 13 h.",The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),h,13,88861,DB00572,Atropine
,26065362,IC50,"The IC50 was 0.15 μg/ml and 0.26 μg/ml for plasma and red cell cholinesterase, respectively.",The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),[μg] / [ml],0.15,88862,DB00572,Atropine
,26065362,IC50,"The IC50 was 0.15 μg/ml and 0.26 μg/ml for plasma and red cell cholinesterase, respectively.",The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),[μg] / [ml],0.26,88863,DB00572,Atropine
,9776957,Steady-state concentrations,Steady-state concentrations were (mean +/- SD) 22.2 +/- 12.3 mg/L.,The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776957/),[mg] / [l],22.2,89250,DB00572,Atropine
,9776957,Volume of distribution,Volume of distribution ranged from 1.7 to 13.8 L/kg and was significantly higher in the more severely poisoned subjects.,The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776957/),[l] / [kg],1.7 to 13.8,89251,DB00572,Atropine
,9776957,Elimination half-life,"Elimination half-life was 3.6 +/- 0.8 hours, and clearance was 0.88 +/- 0.55 L/h/kg.",The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776957/),h,3.6,89252,DB00572,Atropine
,9776957,clearance,"Elimination half-life was 3.6 +/- 0.8 hours, and clearance was 0.88 +/- 0.55 L/h/kg.",The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776957/),[l] / [h·kg],0.88,89253,DB00572,Atropine
,11745922,Cl,Both drugs are highly cleared (Cl between 87 and 150 ml min(-1) kg(-1)) and extensively distributed into tissues (volume of distribution V(ss) between 3 and 15 l kg(-1)).,Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),[ml] / [kg·min],87 and 150,90935,DB00572,Atropine
,11745922,volume of distribution V(ss),Both drugs are highly cleared (Cl between 87 and 150 ml min(-1) kg(-1)) and extensively distributed into tissues (volume of distribution V(ss) between 3 and 15 l kg(-1)).,Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),[l] / [kg],3 and 15,90936,DB00572,Atropine
,11745922,Cl,"In dogs, this holds also true for both drugs (Cl between 34 and 42 ml min(-1) kg(-1), V(ss) between 2 and 10 l kg(-1)), although different dose regimen were applied (i.v. bolus of 0.08 mg kg(-1) vs. infusion of 0.1 mg kg(-1) h(-1) for 3 h).",Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),[ml] / [kg·min],34 and 42,90937,DB00572,Atropine
,11745922,V(ss),"In dogs, this holds also true for both drugs (Cl between 34 and 42 ml min(-1) kg(-1), V(ss) between 2 and 10 l kg(-1)), although different dose regimen were applied (i.v. bolus of 0.08 mg kg(-1) vs. infusion of 0.1 mg kg(-1) h(-1) for 3 h).",Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),[l] / [kg],2 and 10,90938,DB00572,Atropine
,11745922,terminal elimination half-life,"Both ipratropium and tiotropium showed a comparable terminal elimination half-life in rat urine (21-24 h) after single i.v. administration, which was much longer than the corresponding half-life in plasma (6-8 h).",Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),h,21-24,90939,DB00572,Atropine
,11745922,half-life,"Both ipratropium and tiotropium showed a comparable terminal elimination half-life in rat urine (21-24 h) after single i.v. administration, which was much longer than the corresponding half-life in plasma (6-8 h).",Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),h,6-8,90940,DB00572,Atropine
,9234262,Maximal ratios of total-to-non-specific uptake,"Maximal ratios of total-to-non-specific uptake reached values of 1.8 (trachea), 3.2 (bladder), 4.0 (stomach), 4.8 (ileum), 6.6 (pancreas) and 6.9 (submandibular gland) at 5-10 min post-injection; this rank order reflects the tissue densities of M3 cholinoceptors, 4-DAMP did not bind to blood cells and it was rapidly cleared from the circulation (> 90% with a half-life of 0.2 min, the remainder with a half-life of 9.4 min).","Rodent biodistribution and metabolism of tritiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234262/),,1.8,94217,DB00572,Atropine
,9234262,Maximal ratios of total-to-non-specific uptake,"Maximal ratios of total-to-non-specific uptake reached values of 1.8 (trachea), 3.2 (bladder), 4.0 (stomach), 4.8 (ileum), 6.6 (pancreas) and 6.9 (submandibular gland) at 5-10 min post-injection; this rank order reflects the tissue densities of M3 cholinoceptors, 4-DAMP did not bind to blood cells and it was rapidly cleared from the circulation (> 90% with a half-life of 0.2 min, the remainder with a half-life of 9.4 min).","Rodent biodistribution and metabolism of tritiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234262/),,3.2,94218,DB00572,Atropine
,9234262,Maximal ratios of total-to-non-specific uptake,"Maximal ratios of total-to-non-specific uptake reached values of 1.8 (trachea), 3.2 (bladder), 4.0 (stomach), 4.8 (ileum), 6.6 (pancreas) and 6.9 (submandibular gland) at 5-10 min post-injection; this rank order reflects the tissue densities of M3 cholinoceptors, 4-DAMP did not bind to blood cells and it was rapidly cleared from the circulation (> 90% with a half-life of 0.2 min, the remainder with a half-life of 9.4 min).","Rodent biodistribution and metabolism of tritiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234262/),,4.0,94219,DB00572,Atropine
,9234262,Maximal ratios of total-to-non-specific uptake,"Maximal ratios of total-to-non-specific uptake reached values of 1.8 (trachea), 3.2 (bladder), 4.0 (stomach), 4.8 (ileum), 6.6 (pancreas) and 6.9 (submandibular gland) at 5-10 min post-injection; this rank order reflects the tissue densities of M3 cholinoceptors, 4-DAMP did not bind to blood cells and it was rapidly cleared from the circulation (> 90% with a half-life of 0.2 min, the remainder with a half-life of 9.4 min).","Rodent biodistribution and metabolism of tritiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234262/),,4.8,94220,DB00572,Atropine
,9234262,Maximal ratios of total-to-non-specific uptake,"Maximal ratios of total-to-non-specific uptake reached values of 1.8 (trachea), 3.2 (bladder), 4.0 (stomach), 4.8 (ileum), 6.6 (pancreas) and 6.9 (submandibular gland) at 5-10 min post-injection; this rank order reflects the tissue densities of M3 cholinoceptors, 4-DAMP did not bind to blood cells and it was rapidly cleared from the circulation (> 90% with a half-life of 0.2 min, the remainder with a half-life of 9.4 min).","Rodent biodistribution and metabolism of tritiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234262/),,6.6,94221,DB00572,Atropine
,9234262,Maximal ratios of total-to-non-specific uptake,"Maximal ratios of total-to-non-specific uptake reached values of 1.8 (trachea), 3.2 (bladder), 4.0 (stomach), 4.8 (ileum), 6.6 (pancreas) and 6.9 (submandibular gland) at 5-10 min post-injection; this rank order reflects the tissue densities of M3 cholinoceptors, 4-DAMP did not bind to blood cells and it was rapidly cleared from the circulation (> 90% with a half-life of 0.2 min, the remainder with a half-life of 9.4 min).","Rodent biodistribution and metabolism of tritiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234262/),,6.9,94222,DB00572,Atropine
,9234262,half-life,"Maximal ratios of total-to-non-specific uptake reached values of 1.8 (trachea), 3.2 (bladder), 4.0 (stomach), 4.8 (ileum), 6.6 (pancreas) and 6.9 (submandibular gland) at 5-10 min post-injection; this rank order reflects the tissue densities of M3 cholinoceptors, 4-DAMP did not bind to blood cells and it was rapidly cleared from the circulation (> 90% with a half-life of 0.2 min, the remainder with a half-life of 9.4 min).","Rodent biodistribution and metabolism of tritiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234262/),min,0.2,94223,DB00572,Atropine
,9234262,half-life,"Maximal ratios of total-to-non-specific uptake reached values of 1.8 (trachea), 3.2 (bladder), 4.0 (stomach), 4.8 (ileum), 6.6 (pancreas) and 6.9 (submandibular gland) at 5-10 min post-injection; this rank order reflects the tissue densities of M3 cholinoceptors, 4-DAMP did not bind to blood cells and it was rapidly cleared from the circulation (> 90% with a half-life of 0.2 min, the remainder with a half-life of 9.4 min).","Rodent biodistribution and metabolism of tritiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234262/),min,9.4,94224,DB00572,Atropine
,3046815,peak plasma atropine concentration,The peak plasma atropine concentration of 860 +/- 402 pg/ml was reached within 8 minutes in all patients.,Systemic absorption of topically applied ocular atropine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3046815/),[pg] / [ml],860,95063,DB00572,Atropine
,8329252,Cmax,"After nasal and rectal administration, midazolam Cmax was 182 (SD 57) ng ml-1 within 12.6 (5.9) min, and 48 (16) ng ml-1 within 12.1 (6.4) min, respectively.","Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329252/),[ng] / [ml],182,97918,DB00572,Atropine
,8329252,Cmax,"After nasal and rectal administration, midazolam Cmax was 182 (SD 57) ng ml-1 within 12.6 (5.9) min, and 48 (16) ng ml-1 within 12.1 (6.4) min, respectively.","Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329252/),[ng] / [ml],48,97919,DB00572,Atropine
,1941611,elimination T1/2,The pharmacokinetics of equine BuChE administered i.v. in rhesus monkeys revealed an elimination T1/2 of approximately 620 hr.,Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941611/),h,620,102234,DB00572,Atropine
,1941611,LD50,"A third group of monkeys given 253 or 340 nmol (three and four LD50, respectively) of soman after 460 nmol of BuChE required 1 mg/kg of atropine i.v. 10 min postsoman, but recovered completely within 24 hr.",Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941611/),,three,102235,DB00572,Atropine
,9705120,Tmax,"In the control group, Tmax was 31 min and this decreased significantly (P < 0.05) following the administration of metoclopramide.",Acetaminophen as a marker of gastric emptying in ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9705120/),min,31,102516,DB00572,Atropine
,20599794,half-life,"At a dose of 1.2mg/kg the half-life of OpdA was approximately 40 min, with a mean residence time of 57 min.","Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20599794/),min,40,103211,DB00572,Atropine
,20599794,mean residence time,"At a dose of 1.2mg/kg the half-life of OpdA was approximately 40 min, with a mean residence time of 57 min.","Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20599794/),min,57,103212,DB00572,Atropine
,20599794,half-life,"As expected, the half-life did not change with the dose of OpdA given: at doses of 0.15 and 0.45 mg/kg, the half-life of OpdA was 43.1 and 38.9 min, respectively.","Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20599794/),min,43.1,103213,DB00572,Atropine
,20599794,half-life,"As expected, the half-life did not change with the dose of OpdA given: at doses of 0.15 and 0.45 mg/kg, the half-life of OpdA was 43.1 and 38.9 min, respectively.","Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20599794/),min,38.9,103214,DB00572,Atropine
,2020972,elimination half-life,The elimination half-life ranged from 35 min in normal rats to 86 min in sarin-poisoned rats.,Pharmacokinetics and pharmacodynamics of obidoxime in sarin-poisoned rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020972/),min,35,104565,DB00572,Atropine
,2020972,elimination half-life,The elimination half-life ranged from 35 min in normal rats to 86 min in sarin-poisoned rats.,Pharmacokinetics and pharmacodynamics of obidoxime in sarin-poisoned rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020972/),min,86,104566,DB00572,Atropine
,10579809,specific activity,"The active (R)-isomer (pKb = 10.92) was labeled by reacting [(11)C]-CH(3)I with the secondary amine precursor (40-60% decay-corrected radiochemical yield, specific activity 13.0-34.3 TBq/mmol, 45 min after end of bombardment).","Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579809/),[tbq] / [mM],13.0-34.3,110628,DB00572,Atropine
,10579809,standard uptake values (SUVs),"Brain uptake of (R)-[(11)C]-VC-004 was high, standard uptake values (SUVs) ranging from 1.6 in cerebellum to 3.3 in frontal cortex.","Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579809/),,1.6,110629,DB00572,Atropine
,10579809,standard uptake values (SUVs),"Brain uptake of (R)-[(11)C]-VC-004 was high, standard uptake values (SUVs) ranging from 1.6 in cerebellum to 3.3 in frontal cortex.","Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579809/),,3.3,110630,DB00572,Atropine
,10579809,half-life,(R)-[(11)C]VC-004 was rapidly cleared from plasma (92% with a half-life of 0.27 min) and the fraction of total plasma radioactivity representing parent compound decreased from 99% to 42% at 10 min postinjection.,"Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579809/),min,0.27,110631,DB00572,Atropine
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00572,Atropine
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00572,Atropine
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00572,Atropine
,2962877,peak plasma concentration,The peak plasma concentration in three healthy volunteers (means = 322 pg/ml) occurred within 1-3 h.,Radioreceptor assay for determination of the antimuscarinic drug ipratropium bromide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2962877/),[pg] / [ml],322,113674,DB00572,Atropine
,2721508,peak plasma concentration,"Results showed that endobronchial atropine is rapidly absorbed by the pulmonary circulation, resulting in a peak plasma concentration of 48.8 +/- 25.9 ng ml-1 (mean +/- SD) after 2 min, compared to 46.3 +/- 16.7 ng ml-1 in the first min after intravenous injection.",Comparison of intravenous and endobronchial atropine: a pharmacokinetic and -dynamic study in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721508/),[ng] / [ml],48.8,118284,DB00572,Atropine
,2721508,peak plasma concentration,"Results showed that endobronchial atropine is rapidly absorbed by the pulmonary circulation, resulting in a peak plasma concentration of 48.8 +/- 25.9 ng ml-1 (mean +/- SD) after 2 min, compared to 46.3 +/- 16.7 ng ml-1 in the first min after intravenous injection.",Comparison of intravenous and endobronchial atropine: a pharmacokinetic and -dynamic study in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721508/),[ng] / [ml],46.3,118285,DB00572,Atropine
,2721508,bioavailability,Mean bioavailability of atropine following the endobronchial route reached only 23% during the first 6 h when compared to intravenous administration.,Comparison of intravenous and endobronchial atropine: a pharmacokinetic and -dynamic study in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721508/),%,23,118286,DB00572,Atropine
,2905588,isoflurane,The mean isoflurane concentration in group 1 was 0.8 vol% combined with an average alfentanil bolus of 6.8 mg and three additional doses of 1.1-1.4 mg.,[Clinical experiences with alfentanil for balanced anesthesia in upper abdominal surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905588/),vol%,0.8,120712,DB00572,Atropine
,2905588,concentration,The mean isoflurane concentration in group 1 was 0.8 vol% combined with an average alfentanil bolus of 6.8 mg and three additional doses of 1.1-1.4 mg.,[Clinical experiences with alfentanil for balanced anesthesia in upper abdominal surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905588/),vol%,0.8,120713,DB00572,Atropine
,7497908,Plasma half-time,"Plasma half-time (60-70 min), plasma clearance (6-7 ml.kg-1.min-1) and apparent volume of distribution (0.5-0.6 l/kg) of HLö 7 did not differ between the groups, i.e. atropine and soman did not affect the kinetics of the oxime.",Effects of atropine and soman on the pharmacokinetics of the oxime HLö 7 dimethanesulfonate in anesthetized guinea-pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497908/),min,60-70,123064,DB00572,Atropine
,7497908,plasma clearance,"Plasma half-time (60-70 min), plasma clearance (6-7 ml.kg-1.min-1) and apparent volume of distribution (0.5-0.6 l/kg) of HLö 7 did not differ between the groups, i.e. atropine and soman did not affect the kinetics of the oxime.",Effects of atropine and soman on the pharmacokinetics of the oxime HLö 7 dimethanesulfonate in anesthetized guinea-pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497908/),[ml] / [kg·min],6-7,123065,DB00572,Atropine
,7497908,apparent volume of distribution,"Plasma half-time (60-70 min), plasma clearance (6-7 ml.kg-1.min-1) and apparent volume of distribution (0.5-0.6 l/kg) of HLö 7 did not differ between the groups, i.e. atropine and soman did not affect the kinetics of the oxime.",Effects of atropine and soman on the pharmacokinetics of the oxime HLö 7 dimethanesulfonate in anesthetized guinea-pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497908/),[l] / [kg],0.5-0.6,123066,DB00572,Atropine
,3212037,time to peak concentration,"The time to peak concentration was significantly less with exercise than without, 2.9 +/- 2.1 and 13.7 +/- 5.4 min, respectively (p less than 0.005).",Effect of exercise in sheep on the absorption of intramuscular atropine sulfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3212037/),min,2.9,124101,DB00572,Atropine
,3212037,time to peak concentration,"The time to peak concentration was significantly less with exercise than without, 2.9 +/- 2.1 and 13.7 +/- 5.4 min, respectively (p less than 0.005).",Effect of exercise in sheep on the absorption of intramuscular atropine sulfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3212037/),min,13.7,124102,DB00572,Atropine
,3212037,peak serum atropine concentrations,"In addition, peak serum atropine concentrations tended to be higher, 9.7 +/- 1.3 ng/ml with exercise versus 7.1 +/- 2.9 ng/ml without exercise; however, the difference did not attain statistical significance (p less than 0.08).",Effect of exercise in sheep on the absorption of intramuscular atropine sulfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3212037/),[ng] / [ml],9.7,124103,DB00572,Atropine
,3212037,peak serum atropine concentrations,"In addition, peak serum atropine concentrations tended to be higher, 9.7 +/- 1.3 ng/ml with exercise versus 7.1 +/- 2.9 ng/ml without exercise; however, the difference did not attain statistical significance (p less than 0.08).",Effect of exercise in sheep on the absorption of intramuscular atropine sulfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3212037/),[ng] / [ml],7.1,124104,DB00572,Atropine
,2591219,volume of distribution,"Using a randomized, crossover experimental design, it was found that during hypovolemia the mean volume of distribution was reduced by 22% (2.50 +/- 0.62 vs. 3.21 +/- 0.63 L/kg), with no changes in peak serum level, total atropine availability, elimination half-life, or whole-body clearance.",Atropine pharmacokinetics are affected by moderate hemorrhage and hypothyroidism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591219/),[l] / [kg],2.50,127469,DB00572,Atropine
,2591219,volume of distribution,"Using a randomized, crossover experimental design, it was found that during hypovolemia the mean volume of distribution was reduced by 22% (2.50 +/- 0.62 vs. 3.21 +/- 0.63 L/kg), with no changes in peak serum level, total atropine availability, elimination half-life, or whole-body clearance.",Atropine pharmacokinetics are affected by moderate hemorrhage and hypothyroidism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591219/),[l] / [kg],3.21,127470,DB00572,Atropine
,2591219,peak serum atropine concentration,"Hypothyroidism was associated with a significant increase in peak serum atropine concentration (26.4 +/- 3.9 vs. 20.6 +/- 4.9 ng/ml) and drug bioavailability (48.5 +/- 8.8 vs. 30.0 +/- 10.7 ng/ml.h), while the clearance was reduced by 39% (426 +/- 34 vs. 696 +/- 187 ng/ml.min).",Atropine pharmacokinetics are affected by moderate hemorrhage and hypothyroidism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591219/),[ng] / [ml],26.4,127471,DB00572,Atropine
,2591219,peak serum atropine concentration,"Hypothyroidism was associated with a significant increase in peak serum atropine concentration (26.4 +/- 3.9 vs. 20.6 +/- 4.9 ng/ml) and drug bioavailability (48.5 +/- 8.8 vs. 30.0 +/- 10.7 ng/ml.h), while the clearance was reduced by 39% (426 +/- 34 vs. 696 +/- 187 ng/ml.min).",Atropine pharmacokinetics are affected by moderate hemorrhage and hypothyroidism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591219/),[ng] / [ml],20.6,127472,DB00572,Atropine
,2591219,bioavailability,"Hypothyroidism was associated with a significant increase in peak serum atropine concentration (26.4 +/- 3.9 vs. 20.6 +/- 4.9 ng/ml) and drug bioavailability (48.5 +/- 8.8 vs. 30.0 +/- 10.7 ng/ml.h), while the clearance was reduced by 39% (426 +/- 34 vs. 696 +/- 187 ng/ml.min).",Atropine pharmacokinetics are affected by moderate hemorrhage and hypothyroidism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591219/),[ng] / [h·ml],48.5,127473,DB00572,Atropine
,2591219,bioavailability,"Hypothyroidism was associated with a significant increase in peak serum atropine concentration (26.4 +/- 3.9 vs. 20.6 +/- 4.9 ng/ml) and drug bioavailability (48.5 +/- 8.8 vs. 30.0 +/- 10.7 ng/ml.h), while the clearance was reduced by 39% (426 +/- 34 vs. 696 +/- 187 ng/ml.min).",Atropine pharmacokinetics are affected by moderate hemorrhage and hypothyroidism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591219/),[ng] / [h·ml],30.0,127474,DB00572,Atropine
,2591219,clearance,"Hypothyroidism was associated with a significant increase in peak serum atropine concentration (26.4 +/- 3.9 vs. 20.6 +/- 4.9 ng/ml) and drug bioavailability (48.5 +/- 8.8 vs. 30.0 +/- 10.7 ng/ml.h), while the clearance was reduced by 39% (426 +/- 34 vs. 696 +/- 187 ng/ml.min).",Atropine pharmacokinetics are affected by moderate hemorrhage and hypothyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591219/),[ng] / [min·ml],426,127475,DB00572,Atropine
,2591219,clearance,"Hypothyroidism was associated with a significant increase in peak serum atropine concentration (26.4 +/- 3.9 vs. 20.6 +/- 4.9 ng/ml) and drug bioavailability (48.5 +/- 8.8 vs. 30.0 +/- 10.7 ng/ml.h), while the clearance was reduced by 39% (426 +/- 34 vs. 696 +/- 187 ng/ml.min).",Atropine pharmacokinetics are affected by moderate hemorrhage and hypothyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591219/),[ng] / [min·ml],696,127476,DB00572,Atropine
,7802588,tmax,The HLö 7 autoinjectors from Astra Tech and both Binaject autoinjectors from STI functioned well: the bioavailability was complete with tmax values of about 25 min as observed after conventional i.m. injection.,Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802588/),min,25,129585,DB00572,Atropine
,7802588,absorption half-time,"The absorption half-time was about 8 min, elimination t1/2 about 50 min, and Vapp 0.26 l/kg.",Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802588/),min,8,129586,DB00572,Atropine
,7802588,elimination t1/2,"The absorption half-time was about 8 min, elimination t1/2 about 50 min, and Vapp 0.26 l/kg.",Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802588/),min,50,129587,DB00572,Atropine
,7802588,Vapp,"The absorption half-time was about 8 min, elimination t1/2 about 50 min, and Vapp 0.26 l/kg.",Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802588/),[l] / [kg],0.26,129588,DB00572,Atropine
,7802588,urinary recovery,"The urinary recovery of unchanged oximes was 70-80%, the renal clearance being the same as for inulin.",Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802588/),%,70-80,129589,DB00572,Atropine
,3370306,t1/2,Following soman (287 micrograms kg-1) poisoning the t1/2 of HI-6 increased from 8.6 min to 21.6 min and the Vd increased to 0.731 kg-1.,Effect of poisoning by soman (pinacolyl methylphosphonofluoridate) on the serum half-life of the cholinesterase reactivator HI-6 in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370306/),min,8.6,133950,DB00572,Atropine
,3370306,t1/2,Following soman (287 micrograms kg-1) poisoning the t1/2 of HI-6 increased from 8.6 min to 21.6 min and the Vd increased to 0.731 kg-1.,Effect of poisoning by soman (pinacolyl methylphosphonofluoridate) on the serum half-life of the cholinesterase reactivator HI-6 in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370306/),min,21.6,133951,DB00572,Atropine
,3370306,Vd,Following soman (287 micrograms kg-1) poisoning the t1/2 of HI-6 increased from 8.6 min to 21.6 min and the Vd increased to 0.731 kg-1.,Effect of poisoning by soman (pinacolyl methylphosphonofluoridate) on the serum half-life of the cholinesterase reactivator HI-6 in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370306/),1/[kg],0.731,133952,DB00572,Atropine
,28343895,K027,"According to the results, both oximes had similar Cmax (K027: 106±19μg/mL and K203: 111±8μg/mL) in Tmax 19±5min, respectively, in 22±3min.",Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[μg] / [ml],106,134219,DB00572,Atropine
,28343895,K203,"According to the results, both oximes had similar Cmax (K027: 106±19μg/mL and K203: 111±8μg/mL) in Tmax 19±5min, respectively, in 22±3min.",Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[μg] / [ml],111,134220,DB00572,Atropine
,28343895,Tmax,"According to the results, both oximes had similar Cmax (K027: 106±19μg/mL and K203: 111±8μg/mL) in Tmax 19±5min, respectively, in 22±3min.",Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),min,19,134221,DB00572,Atropine
,28343895,Tmax,"According to the results, both oximes had similar Cmax (K027: 106±19μg/mL and K203: 111±8μg/mL) in Tmax 19±5min, respectively, in 22±3min.",Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),min,22,134222,DB00572,Atropine
,28343895,Bioavailability,Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minμg/mL) was halved compared to oxime K203 (16938±795minμg/mL).,Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[minμg] / [ml],8389,134223,DB00572,Atropine
,28343895,Bioavailability,Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minμg/mL) was halved compared to oxime K203 (16938±795minμg/mL).,Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[minμg] / [ml],16938,134224,DB00572,Atropine
,28343895,AUCtotal,Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minμg/mL) was halved compared to oxime K203 (16938±795minμg/mL).,Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[minμg] / [ml],8389,134225,DB00572,Atropine
,28343895,AUCtotal,Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minμg/mL) was halved compared to oxime K203 (16938±795minμg/mL).,Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[minμg] / [ml],16938,134226,DB00572,Atropine
,11348483,peak plasma concentration,The peak plasma concentration of 2-PAM at 1 min was in the range of 189.5-196.6 microg/mL which declined to 9.22-9.98 microg/mL at 4 h.,Pharmacokinetics and dosage regimen of 2-pyridine aldoxime in Bubalus bubalis intoxicated with fenitrothion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348483/),[μg] / [ml],189.5-196.6,134498,DB00572,Atropine
,11348483,peak plasma concentration,The peak plasma concentration of 2-PAM at 1 min was in the range of 189.5-196.6 microg/mL which declined to 9.22-9.98 microg/mL at 4 h.,Pharmacokinetics and dosage regimen of 2-pyridine aldoxime in Bubalus bubalis intoxicated with fenitrothion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348483/),[μg] / [ml],9.22-9.98,134499,DB00572,Atropine
,11348483,elimination half-life,"The values of elimination half-life, Vd(area) and total body clearance were 2.41-2.67 h, 0.77-0.95 L/kg and 227.5-245.7 mL/kg/h, respectively.",Pharmacokinetics and dosage regimen of 2-pyridine aldoxime in Bubalus bubalis intoxicated with fenitrothion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348483/),h,2.41-2.67,134500,DB00572,Atropine
,11348483,Vd(area),"The values of elimination half-life, Vd(area) and total body clearance were 2.41-2.67 h, 0.77-0.95 L/kg and 227.5-245.7 mL/kg/h, respectively.",Pharmacokinetics and dosage regimen of 2-pyridine aldoxime in Bubalus bubalis intoxicated with fenitrothion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348483/),[l] / [kg],0.77-0.95,134501,DB00572,Atropine
,11348483,total body clearance,"The values of elimination half-life, Vd(area) and total body clearance were 2.41-2.67 h, 0.77-0.95 L/kg and 227.5-245.7 mL/kg/h, respectively.",Pharmacokinetics and dosage regimen of 2-pyridine aldoxime in Bubalus bubalis intoxicated with fenitrothion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348483/),[ml] / [h·kg],227.5-245.7,134502,DB00572,Atropine
,11348483,binding capacity,"The binding capacity of 2-PAM to plasma proteins of fenitrothion-intoxicated buffalo calves and dissociation rate constant of protein drug complex were 0.015 x 10(-6) mol/g and 2.367 x 10(-6) mol, respectively.",Pharmacokinetics and dosage regimen of 2-pyridine aldoxime in Bubalus bubalis intoxicated with fenitrothion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348483/),[mol] / [g],0.015 x 10(-6),134503,DB00572,Atropine
,11348483,dissociation rate constant,"The binding capacity of 2-PAM to plasma proteins of fenitrothion-intoxicated buffalo calves and dissociation rate constant of protein drug complex were 0.015 x 10(-6) mol/g and 2.367 x 10(-6) mol, respectively.",Pharmacokinetics and dosage regimen of 2-pyridine aldoxime in Bubalus bubalis intoxicated with fenitrothion. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348483/),mol,2.367 x 10(-6),134504,DB00572,Atropine
,23897549,run time,"The separation was accomplished on a Hanbon Hedera CN column (100 × 4.6 mm, 5 μm) and the run time was 4 min.",Development and validation of a rapid and sensitive assay for the determination of anisodamine in 50 μL of beagle dog plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897549/),min,4,140217,DB00572,Atropine
,22691110,area under the curve concentration,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),[h·ng] / [ml],20.1,141529,DB00572,Atropine
,22691110,AUTO,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),[h·ng] / [ml],23.7,141530,DB00572,Atropine
,22691110,maximum concentration reached,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),,7.7,141531,DB00572,Atropine
,22691110,AUTO,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),[ng] / [ml],11.0,141532,DB00572,Atropine
,22691110,time to reach maximum concentration,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),,0.25,141533,DB00572,Atropine
,22691110,AUTO,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),h,0.19,141534,DB00572,Atropine
,22691110,AUTO,"Pharmacodynamic results were as follows: maximum increase in heart rate, DPIA=18±12, AUTO=23±13 beats/min; average change in 1-sec forced expiratory volume at 30 min, DPIA=0.16±0.22 L, AUTO=0.11±0.29 L.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),[beats] / [min],23,141535,DB00572,Atropine
,22691110,AUTO,"Pharmacodynamic results were as follows: maximum increase in heart rate, DPIA=18±12, AUTO=23±13 beats/min; average change in 1-sec forced expiratory volume at 30 min, DPIA=0.16±0.22 L, AUTO=0.11±0.29 L.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),l,0.11,141536,DB00572,Atropine
,22691110,relative bioavailability,The relative bioavailability for DPIA was 87% (based on output dose).,Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),%,87,141537,DB00572,Atropine
,1687880,low detection limit,The low detection limit of this method in the patient was 3 ng/mL.,Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687880/),[ng] / [ml],3,142308,DB00572,Atropine
less,7224209,rate of increase in twitch tension,Twitch tension rapidly increased to a plateau (a rate of increase in twitch tension of less than 2 per cent of control per min) which was sustained in all cases.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),%,2,142422,DB00572,Atropine
,7224209,time to plateau,The mean time to plateau for edrophonium was 2.9 +/- 0.21 (+/-SE) min as compared to 6.1 +/- 0.75 min for neostigmine.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,2.9,142423,DB00572,Atropine
,7224209,time to plateau,The mean time to plateau for edrophonium was 2.9 +/- 0.21 (+/-SE) min as compared to 6.1 +/- 0.75 min for neostigmine.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,6.1,142424,DB00572,Atropine
,7224209,elimination half-lives,"The elimination half-lives of edrophonium and neostigmine were 110 +/- 34 min (mean +/- SD) and 77 +/- 47 min, respectively.",Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,110,142425,DB00572,Atropine
,7224209,elimination half-lives,"The elimination half-lives of edrophonium and neostigmine were 110 +/- 34 min (mean +/- SD) and 77 +/- 47 min, respectively.",Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,77,142426,DB00572,Atropine
,19681868,maximum concentration (C(max)),"The maximum concentration (C(max)) of diazepam after avizafone injection was higher than that obtained after injection of diazepam itself (231 vs. 148 ng.mL(-1)), while area under the curve (AUC) values were equal.",Bioavailability of diazepam after intramuscular injection of its water-soluble prodrug alone or with atropine-pralidoxime in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19681868/),[ng] / [ml],231,143771,DB00572,Atropine
,19681868,maximum concentration (C(max)),"The maximum concentration (C(max)) of diazepam after avizafone injection was higher than that obtained after injection of diazepam itself (231 vs. 148 ng.mL(-1)), while area under the curve (AUC) values were equal.",Bioavailability of diazepam after intramuscular injection of its water-soluble prodrug alone or with atropine-pralidoxime in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19681868/),[ng] / [ml],148,143772,DB00572,Atropine
,33521988,Cmax,The noncompartmental pharmacokinetic study of atropine performed in 1 patient highlighted that systemic absorption of sublingual atropine was effective (Cmax [1 h] = 2.2 ng mL-1 ; approximately) after a single dose of 1 mg.,Atropine-induced toxicity after off-label sublingual administration of eyedrop for sialorrhoea treatment in neurological disabled patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33521988/),[ng] / [ml],2.2,143936,DB00572,Atropine
,26795744,elimination half-life,Her levetiracetam concentration was 463 mcg/ml 8 h post ingestion (therapeutic range 10-40 mcg/ml) and her concentration-time data best fitted a one-compartment model with first-order input and an elimination half-life of 10.4 h.,Cardiovascular toxicity with levetiracetam overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795744/),h,10.4,145038,DB00572,Atropine
,9292288,heart rate,"In the ICU, atropine sulphate was administered i.v. upon demand according to the endpoints: no bronchorrhoea, dry mucous membranes, no axillary sweating, heart rate of about 100/min.","Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9292288/),1/[min],100,154423,DB00572,Atropine
,9292288,apparent half-time,"Still, the reactivation rate, with an apparent half-time of some 3 min, is twice that estimated for a tenfold higher pralidoxime concentration.","Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9292288/),min,3,154424,DB00572,Atropine
,9705889,LCt50,The animals were exposed for 4-8 min to 0.4-0.8 LCt50 of C(+/-)P(+/-)-soman.,Inhalation toxicokinetics of soman stereoisomers in the atropinized guinea pig with nose-only exposure to soman vapor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9705889/),,0.4-0.8,155469,DB00572,Atropine
,3733273,t1/2,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),min,1-2,156391,DB00572,Atropine
,3733273,Vd beta,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),[l] / [kg],2.6,156392,DB00572,Atropine
,3733273,Cl total,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),[l] / [h·kg],0.310-0.384,156393,DB00572,Atropine
,3733273,elimination phase half-life,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),h,6.5,156394,DB00572,Atropine
,1840322,volume of the central compartment,The volume of the central compartment and the clearance of both drugs were very similar (about 3 L/kg and 3.5 L/h/kg respectively) while the steady state volume of distribution and the terminal half-life of atropine were higher than those of ipratropium.,Plasma kinetics of atropine and ipratropium in rats after different routes of administration evaluated by a radioreceptor assay. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840322/),[l] / [kg],3,156707,DB00572,Atropine
,1840322,clearance,The volume of the central compartment and the clearance of both drugs were very similar (about 3 L/kg and 3.5 L/h/kg respectively) while the steady state volume of distribution and the terminal half-life of atropine were higher than those of ipratropium.,Plasma kinetics of atropine and ipratropium in rats after different routes of administration evaluated by a radioreceptor assay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840322/),[l] / [h·kg],3.5,156708,DB00572,Atropine
,6734699,elimination half-life,"After intravenous dosing, the mean (+/- SD) elimination half-life (2.14 +/- 1.24 h) showed a statistically significant trend to increase with age in the subjects older than 60 years.",Pharmacokinetics of midazolam in the aged. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),h,2.14,160585,DB00572,Atropine
,6734699,clearance,"While the mean (+/- SD) clearance value (0.30 +/- 0.19 l kg-1h-1) tended to fall with age in the elderly subjects, this trend was not statistically significant.",Pharmacokinetics of midazolam in the aged. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),[l] / [kg],0.30,160586,DB00572,Atropine
,6734699,Apparent volume of distribution,"Apparent volume of distribution did not appear to be related to advancing age beyond 60 years, and this parameter (mean +/- SD) did not differ to a statistically significant extent between the aged subjects (0.77 +/- 0.47 l kg-1) and the young subjects studied previously (1.09 +/- 0.58 l kg-1).",Pharmacokinetics of midazolam in the aged. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),[l] / [kg],0.77,160587,DB00572,Atropine
,6734699,Apparent volume of distribution,"Apparent volume of distribution did not appear to be related to advancing age beyond 60 years, and this parameter (mean +/- SD) did not differ to a statistically significant extent between the aged subjects (0.77 +/- 0.47 l kg-1) and the young subjects studied previously (1.09 +/- 0.58 l kg-1).",Pharmacokinetics of midazolam in the aged. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),[l] / [kg],1.09,160588,DB00572,Atropine
,6734699,F,"Bioavailability appeared incomplete (F = 0.59 +/- 0.15, mean +/- SD), possibly due to saturable elimination of the drug at the higher plasma levels which were obtained after intravenous midazolam.",Pharmacokinetics of midazolam in the aged. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),,0.59,160589,DB00572,Atropine
,6734699,Oral bioavailability,"Oral bioavailability, relative to intravenous, was 0.34 +/- 0.17, (mean +/- SD), with an appreciable but variable lag time (0.74 +/- 0.40 h, mean +/- SD).",Pharmacokinetics of midazolam in the aged. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),,0.34,160590,DB00572,Atropine
,6734699,lag time,"Oral bioavailability, relative to intravenous, was 0.34 +/- 0.17, (mean +/- SD), with an appreciable but variable lag time (0.74 +/- 0.40 h, mean +/- SD).",Pharmacokinetics of midazolam in the aged. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),h,0.74,160591,DB00572,Atropine
,6626697,plasma half-life,The plasma half-life following intravenous administration was 31 min (monoexponential equation) with little effect of enterohepatic recycling noted.,Absorption and disposition characteristics of nitrofurantoin in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626697/),min,31,162225,DB00572,Atropine
,6626697,absorption half-lives,The absorption half-lives following tablet administration ranged from 30 to 72 min and were not affected by food or atropine.,Absorption and disposition characteristics of nitrofurantoin in dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626697/),min,30 to 72,162226,DB00572,Atropine
,6626697,elimination half-lives,The elimination half-lives following oral administration ranged from 19 to 87 min with significantly prolonged elimination when solid dosage forms were administered compared to solution.,Absorption and disposition characteristics of nitrofurantoin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626697/),min,19 to 87,162227,DB00572,Atropine
,6626697,extent of absorption,The extent of absorption ranged from 38 to 120 per cent.,Absorption and disposition characteristics of nitrofurantoin in dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626697/),%,38 to 120,162228,DB00572,Atropine
,1800018,maximal serum concentration,"After i.v. administration of aminophylline 12.5 mg/kg, i.m. atropine 1 mg/kg decreased significantly the maximal serum concentration of theophylline from 23.6 +/- 1.1 to 19.6 +/- 1.1 mg/l, and increased that of theophylline at the time of 6 and 8 hours after injection.",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[mg] / [l],23.6,163548,DB00572,Atropine
,1800018,maximal serum concentration,"After i.v. administration of aminophylline 12.5 mg/kg, i.m. atropine 1 mg/kg decreased significantly the maximal serum concentration of theophylline from 23.6 +/- 1.1 to 19.6 +/- 1.1 mg/l, and increased that of theophylline at the time of 6 and 8 hours after injection.",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[mg] / [l],19.6,163549,DB00572,Atropine
,1800018,K (elimination rate constant),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),1/[h],0.23,163550,DB00572,Atropine
,1800018,K (elimination rate constant),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),1/[h],0.19,163551,DB00572,Atropine
,1800018,t1/2 (half life),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),h,3.04,163552,DB00572,Atropine
,1800018,t1/2 (half life),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),h,3.66,163553,DB00572,Atropine
,1800018,Cl (clearance),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[l] / [h·kg],0.26,163554,DB00572,Atropine
,1800018,Cl (clearance),"After i.v. aminophylline administration without or with atropine, the pharmacokinetic parameters of theophylline calculated using a one compartment open model were: K (elimination rate constant) = 0.23 +/- 0.03, 0.19 +/- 0.02/h; t1/2 (half life) = 3.04 +/- 0.40, 3.66 +/- 0.40 h; Cl (clearance) = 0.26 +/- 0.04, 0.23 +/- 0.03 l/kg/h, respectively (P less than 0.01).",The effects of atropine on pharmacokinetics of theophylline in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800018/),[l] / [h·kg],0.23,163555,DB00572,Atropine
,11936581,terminal half-life,"Blood aldicarb level was 3.11 microg/mL at T0 and peaked at T0+3.5 h (3.22 microg/mL), then followed a two-slope decay with a terminal half-life of ca. 20 h.",Repeated measurements of aldicarb in blood and urine in a case of nonfatal poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936581/),h,20,169378,DB00572,Atropine
,11936581,peak level,Aldicarb was detected in all urine samples (peak level: 6.95 microg/mL at T0+31.5 h) and was still present at the time of discharge.,Repeated measurements of aldicarb in blood and urine in a case of nonfatal poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936581/),[μg] / [ml],6.95,169379,DB00572,Atropine
,2143593,peak concentrations,The peak concentrations were about 50% higher (380 +/- 153 pg/ml) in patients than in control subjects (245 +/- 134 pg/ml).,Vasomotor rhinitis and the systemic absorption of ipratropium bromide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2143593/),[pg] / [ml],380,172750,DB00572,Atropine
,2143593,peak concentrations,The peak concentrations were about 50% higher (380 +/- 153 pg/ml) in patients than in control subjects (245 +/- 134 pg/ml).,Vasomotor rhinitis and the systemic absorption of ipratropium bromide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2143593/),[pg] / [ml],245,172751,DB00572,Atropine
,2143593,AUCs/0-15 min,The AUCs/0-15 min (1970 +/- 1140 pg/ml X min) in patients were about 100% higher than in the control subjects (960 +/- 560 pg/ml X min).,Vasomotor rhinitis and the systemic absorption of ipratropium bromide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2143593/),[pg] / [min·ml],1970,172752,DB00572,Atropine
,2143593,AUCs/0-15 min,The AUCs/0-15 min (1970 +/- 1140 pg/ml X min) in patients were about 100% higher than in the control subjects (960 +/- 560 pg/ml X min).,Vasomotor rhinitis and the systemic absorption of ipratropium bromide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2143593/),[pg] / [min·ml],960,172753,DB00572,Atropine
,6821619,initial half-life,"In the eight patients studied, the initial half-life was 1.0 +/- 0.3 min and the terminal half-life was 46.4 +/- 6.5 min (mean +/- SEM).",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),min,1.0,173568,DB00572,Atropine
,6821619,terminal half-life,"In the eight patients studied, the initial half-life was 1.0 +/- 0.3 min and the terminal half-life was 46.4 +/- 6.5 min (mean +/- SEM).",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),min,46.4,173569,DB00572,Atropine
,6821619,Total body clearance,"Total body clearance of pyridostigmine was 8.7 +/- 1.5 ml min-1 kg-1, and the total apparent volume of distribution was 536 +/- 80 ml kg-1.",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),[ml] / [kg·min],8.7,173570,DB00572,Atropine
,6821619,total apparent volume of distribution,"Total body clearance of pyridostigmine was 8.7 +/- 1.5 ml min-1 kg-1, and the total apparent volume of distribution was 536 +/- 80 ml kg-1.",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),[ml] / [kg],536,173571,DB00572,Atropine
,24735001,heart rate,"Initial vitals: temperature, 36.8°C; blood pressure, 103/56 mmHg; heart rate, 140/min; respiratory rate, 36/min; oxygen saturation, 97%.",Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735001/),1/[min],140,174902,DB00572,Atropine
,24735001,respiratory rate,"Initial vitals: temperature, 36.8°C; blood pressure, 103/56 mmHg; heart rate, 140/min; respiratory rate, 36/min; oxygen saturation, 97%.",Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735001/),1/[min],36,174903,DB00572,Atropine
,24735001,oxygen saturation,"Initial vitals: temperature, 36.8°C; blood pressure, 103/56 mmHg; heart rate, 140/min; respiratory rate, 36/min; oxygen saturation, 97%.",Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735001/),%,97,174904,DB00572,Atropine
,24735001,elimination of half-life,Donepezil has a prolonged elimination of half-life in adults of approximately 70 hours.,Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735001/),h,70,174905,DB00572,Atropine
,1482283,shelf-life,"HLö 7 dimethanesulfonate is the first water-soluble salt of HLö 7 that should be suitable for the wet/dry autoinjector technology, because aqueous solutions of HLö 7 are not very stable (calculated shelf-life 0.2 years when stored at 8 degrees C, 1 M solution, pH 2.5).","HLö 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482283/),years,0.2,175597,DB00572,Atropine
,1482283,mean survival time,The mean survival time of anaesthetized guinea-pigs exposed to 5 LD50 soman (6.3 min) was increased by atropine (27 min) and atropine + HLö (57 min).,"HLö 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482283/),min,6.3,175598,DB00572,Atropine
,1482283,mean survival time,The mean survival time of anaesthetized guinea-pigs exposed to 5 LD50 soman (6.3 min) was increased by atropine (27 min) and atropine + HLö (57 min).,"HLö 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482283/),min,27,175599,DB00572,Atropine
,1482283,mean survival time,The mean survival time of anaesthetized guinea-pigs exposed to 5 LD50 soman (6.3 min) was increased by atropine (27 min) and atropine + HLö (57 min).,"HLö 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482283/),min,57,175600,DB00572,Atropine
,6486504,ED50,The reported values for ED50 for edrophonium (obtained under similar anesthetic conditions) is 128 micrograms/kg for adults.,Clinical pharmacology of edrophonium in infants and children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[μg] / [kg],128,176742,DB00572,Atropine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],17.8,176743,DB00572,Atropine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],14.2,176744,DB00572,Atropine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],8.3,176745,DB00572,Atropine
,2524387,Vc,"After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),l,25.9,182494,DB00572,Atropine
,2524387,V alpha,"After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),l,13.1,182495,DB00572,Atropine
,2524387,V beta,"After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),l,3.38,182496,DB00572,Atropine
,2524387,t1/2 alpha,"After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),min,3.85,182497,DB00572,Atropine
,2524387,t1/2 beta,"After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),min,98.4,182498,DB00572,Atropine
,2524387,AUC,"After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),[h·ng] / [ml],15.0,182499,DB00572,Atropine
,2524387,kel,"After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),[l] / [h],11.8,182500,DB00572,Atropine
,2524387,total clearance,"After i.v. administration the kinetic parameters were: Vc = 25.9 l, V alpha = 13.1 l, V beta = 3.38 l, t1/2 alpha = 3.85 min, t1/2 beta = 98.4 min, AUC = 15.0 h.ng/ml, kel = 11.8 l/h and total clearance is 2325 ml/min.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),[ml] / [min],2325,182501,DB00572,Atropine
,2524387,bioavailability,The bioavailability was 3.3% (range 0.9-6.1%) on comparing the plasma AUCs following i.v. and 20 mg oral administration.,Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),%,3.3,182502,DB00572,Atropine
,2524387,apparent systemic availability,"Following oral administration, the apparent systemic availability was around 2%, and after inhalation it was 6.9%.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),%,2,182503,DB00572,Atropine
,2524387,apparent systemic availability,"Following oral administration, the apparent systemic availability was around 2%, and after inhalation it was 6.9%.",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),%,6.9,182504,DB00572,Atropine
,2524387,heart rate,"In comparison with oral placebo administration, only after i.v. administration was there a significant change in heart rate (from 63.7 to 90.2 beats/min).",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),[beats] / [min],63.7,182505,DB00572,Atropine
,2524387,heart rate,"In comparison with oral placebo administration, only after i.v. administration was there a significant change in heart rate (from 63.7 to 90.2 beats/min).",Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524387/),[beats] / [min],90.2,182506,DB00572,Atropine
,8331202,biologic half-life,"As the serum creatinine concentration returned slowly to baseline with good diuresis, the concentration of atenolol decreased (biologic half-life = 2.95 days) and the blood pressure gradually recovered.",Impaired elimination of atenolol in a nephropathic patient with self-medication overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331202/),d,2.95,184252,DB00572,Atropine
,8000380,bioavailability,"The bioavailability of the SR tablet accounted for 76% in the regulated-dogs and 71% in intact dogs relative to that of the conventional tablet in the regulated-dogs, respectively, but no significant difference was detectable between these values.",Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8000380/),%,76,189383,DB00572,Atropine
,8000380,bioavailability,"The bioavailability of the SR tablet accounted for 76% in the regulated-dogs and 71% in intact dogs relative to that of the conventional tablet in the regulated-dogs, respectively, but no significant difference was detectable between these values.",Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8000380/),%,71,189384,DB00572,Atropine
,29127032,protection,"The treatment containing HI-6 gave a similar level of protection at 6h as previously determined at 24h (protection ratios 3.9 and 2.9, respectively).",Efficacy of the antinicotinic compound MB327 against soman poisoning - Importance of experimental end point. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127032/),,3,191326,DB00572,Atropine
,29127032,protection,"The treatment containing HI-6 gave a similar level of protection at 6h as previously determined at 24h (protection ratios 3.9 and 2.9, respectively).",Efficacy of the antinicotinic compound MB327 against soman poisoning - Importance of experimental end point. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127032/),,2,191327,DB00572,Atropine
,3740650,Peak concentrations,"Peak concentrations (mean +/- SD) were 11.5 +/- 3.4, 16.4 +/- 6.2, and 18.0 +/- 3.1 ng/ml for the 2, 4, and 6 mg doses, and 11.7 +/- 2.5 ng/ml for the IM dose.",Comparative absorption of inhaled and intramuscularly administered atropine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740650/),[ng] / [ml],11.5,192349,DB00572,Atropine
,3740650,Peak concentrations,"Peak concentrations (mean +/- SD) were 11.5 +/- 3.4, 16.4 +/- 6.2, and 18.0 +/- 3.1 ng/ml for the 2, 4, and 6 mg doses, and 11.7 +/- 2.5 ng/ml for the IM dose.",Comparative absorption of inhaled and intramuscularly administered atropine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740650/),[ng] / [ml],16.4,192350,DB00572,Atropine
,3740650,Peak concentrations,"Peak concentrations (mean +/- SD) were 11.5 +/- 3.4, 16.4 +/- 6.2, and 18.0 +/- 3.1 ng/ml for the 2, 4, and 6 mg doses, and 11.7 +/- 2.5 ng/ml for the IM dose.",Comparative absorption of inhaled and intramuscularly administered atropine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740650/),[ng] / [ml],18.0,192351,DB00572,Atropine
,3740650,Peak concentrations,"Peak concentrations (mean +/- SD) were 11.5 +/- 3.4, 16.4 +/- 6.2, and 18.0 +/- 3.1 ng/ml for the 2, 4, and 6 mg doses, and 11.7 +/- 2.5 ng/ml for the IM dose.",Comparative absorption of inhaled and intramuscularly administered atropine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740650/),[ng] / [ml],11.7,192352,DB00572,Atropine
,3740650,time to peak concentration,"The time to peak concentration for each dose was similar (mean, 0.8 to 1.9 h).",Comparative absorption of inhaled and intramuscularly administered atropine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740650/),h,0.8 to 1.9,192353,DB00572,Atropine
,3740650,AUC ratio,The AUC ratio of the 2-mg inhaled and IM doses was 1.11 +/- 0.41.,Comparative absorption of inhaled and intramuscularly administered atropine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740650/),,1.11,192354,DB00572,Atropine
,6612735,half-life of the elimination,The half-life of the elimination of EPN from plasma was 16.5 days corresponding to a constant rate value of 0.04 day-1.,"The absorption, distribution, excretion, and metabolism of a single oral dose of O-ethyl O-4-nitrophenyl phenylphosphonothioate in hens. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612735/),d,16.5,192858,DB00572,Atropine
,6612735,constant rate value,The half-life of the elimination of EPN from plasma was 16.5 days corresponding to a constant rate value of 0.04 day-1.,"The absorption, distribution, excretion, and metabolism of a single oral dose of O-ethyl O-4-nitrophenyl phenylphosphonothioate in hens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612735/),1/[d],0.04,192859,DB00572,Atropine
,33827566,steady-state volume of distribution,The typical value was 1.7 L/kg for the steady-state volume of distribution.,"Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827566/),[l] / [kg],1.7,208672,DB00572,Atropine
,33827566,Total plasma clearance,Total plasma clearance was 1.9 L/h‧kg.,"Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827566/),[l] / [h‧kg],1.9,208673,DB00572,Atropine
,33827566,bioavailability,"The bioavailability after administration of an ophthalmic preparation as an eye drop or topical infusion were 69 and 68%, respectively.","Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827566/),%,69,208674,DB00572,Atropine
,33827566,bioavailability,"The bioavailability after administration of an ophthalmic preparation as an eye drop or topical infusion were 69 and 68%, respectively.","Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827566/),%,68,208675,DB00572,Atropine
,33827566,terminal half-life,The terminal half-life was short (0.8 h).,"Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827566/),h,0.8,208676,DB00572,Atropine
,7446137,recovery,"The recovery of atropine was near 100% when the drug was added at different concentrations to normal, pooled human plasma.",Radioimmunoassay for atropine and l-hyoscyamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),%,100,208739,DB00572,Atropine
,7446137,t 1/2,A biexponential serum decay curve was demonstrated in both cases with a very rapid distribution phase (t 1/2 0.63 and 1.38 min.) and a much slower elimination phase (t 1/2 1.86 and 2.09 hrs.).,Radioimmunoassay for atropine and l-hyoscyamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),min,0.63,208740,DB00572,Atropine
,7446137,t 1/2,A biexponential serum decay curve was demonstrated in both cases with a very rapid distribution phase (t 1/2 0.63 and 1.38 min.) and a much slower elimination phase (t 1/2 1.86 and 2.09 hrs.).,Radioimmunoassay for atropine and l-hyoscyamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),min,1.38,208741,DB00572,Atropine
,7446137,t 1/2,A biexponential serum decay curve was demonstrated in both cases with a very rapid distribution phase (t 1/2 0.63 and 1.38 min.) and a much slower elimination phase (t 1/2 1.86 and 2.09 hrs.).,Radioimmunoassay for atropine and l-hyoscyamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),h,1.86,208742,DB00572,Atropine
,7446137,t 1/2,A biexponential serum decay curve was demonstrated in both cases with a very rapid distribution phase (t 1/2 0.63 and 1.38 min.) and a much slower elimination phase (t 1/2 1.86 and 2.09 hrs.).,Radioimmunoassay for atropine and l-hyoscyamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),h,2.09,208743,DB00572,Atropine
,2800990,apparent elimination phase half-life,The apparent elimination phase half-life of scopolamine in serum was only around 1 h.,Pharmacokinetics of scopolamine during caesarean section: relationship between serum concentration and effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800990/),h,1,210036,DB00572,Atropine
,22527350,maximum plasma concentrations,Methantheline reached maximum plasma concentrations of approximately 25 ng/ml after 2.5-3 h and was eliminated at an apparent half-life of approximately 2 h.,Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527350/),[ng] / [ml],25,210062,DB00572,Atropine
,22527350,apparent half-life,Methantheline reached maximum plasma concentrations of approximately 25 ng/ml after 2.5-3 h and was eliminated at an apparent half-life of approximately 2 h.,Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527350/),h,2,210063,DB00572,Atropine
,22527350,"concentration at half maximum effects, EC₅₀)","Methantheline reduced salivation at a potency (methantheline concentration at half maximum effects, EC₅₀) of 5.5 ng/ml in accordance with it plasma concentration.",Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527350/),[ng] / [ml],5.5,210064,DB00572,Atropine
,8087216,Half-life,Half-life was 8.6 +/- 2.4 hours and tended to decrease with age.,[Pharmacokinetics of diphemanil methylsulfate in infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087216/),h,8.6,211544,DB00572,Atropine
,8087216,half-life,"The peak plasma concentration occurred in the sixth younger infant at 2.9 hours, with a half-life of 17.2 hours.",[Pharmacokinetics of diphemanil methylsulfate in infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087216/),h,17.2,211545,DB00572,Atropine
,8087216,Renal clearance,Renal clearance was high (0.3 l/h/kg).,[Pharmacokinetics of diphemanil methylsulfate in infants]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087216/),[l] / [h·kg],0.3,211546,DB00572,Atropine
,2813282,elimination half-life,The elimination half-life was 2.27 hr.,Intramuscular atropine in elderly people: pharmacokinetic studies using the radioreceptor assay and some pharmacodynamic responses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813282/),h,2.27,213803,DB00572,Atropine
,134721,half-life of elimination,The half-life of elimination lay between 3.2 and 3.8 h for all routes of administration.,[Studies on pharmacokinetics and biotransformation of ipratropiumbromide in man (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/134721/),h,3.2 and 3.8,214618,DB00572,Atropine
,134721,Cumulative renal excretion,"Cumulative renal excretion was 9.3% following oral administration, 72.1% following i.v. route and 3.2% after inhalation.",[Studies on pharmacokinetics and biotransformation of ipratropiumbromide in man (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134721/),%,9.3,214619,DB00572,Atropine
,134721,Cumulative renal excretion,"Cumulative renal excretion was 9.3% following oral administration, 72.1% following i.v. route and 3.2% after inhalation.",[Studies on pharmacokinetics and biotransformation of ipratropiumbromide in man (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134721/),%,72.1,214620,DB00572,Atropine
,134721,Cumulative renal excretion,"Cumulative renal excretion was 9.3% following oral administration, 72.1% following i.v. route and 3.2% after inhalation.",[Studies on pharmacokinetics and biotransformation of ipratropiumbromide in man (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134721/),%,3.2,214621,DB00572,Atropine
,1610996,Total sampling time,"Total sampling time before CPB (45 to 75 minutes) was too short to allow full characterization of the pharmacokinetics of alfentanil, but allowed estimation of the initial volume of distribution.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),min,45 to 75,214806,DB00572,Atropine
,1610996,initial,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],68,214807,DB00572,Atropine
,1610996,initial,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],235,214808,DB00572,Atropine
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],68,214809,DB00572,Atropine
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],80,214810,DB00572,Atropine
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],235,214811,DB00572,Atropine
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],179,214812,DB00572,Atropine
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],17.9,214813,DB00572,Atropine
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],18.3,214814,DB00572,Atropine
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],11.1,214815,DB00572,Atropine
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],12.9,214816,DB00572,Atropine
,2979128,maximum inspired concentration,"After intubation, anesthesia was maintained with nitrous oxide-oxygen and halothane to a maximum inspired concentration of 0.6%.",Alfentanil in infants and children with congenital heart defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),%,0.6,216495,DB00572,Atropine
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],8.2,216496,DB00572,Atropine
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],6.3,216497,DB00572,Atropine
up to,30218682,LD50,"A better efficacy of the HI-6 DMS combination was clearly observed: up to 5 LD50 of VR (i.m.), a single administration of the HI-6 DMS combination, shortly after the onset of clinical signs, prevented death of the four intoxicated animals.",Superior efficacy of HI-6 dimethanesulfonate over pralidoxime methylsulfate against Russian VX poisoning in cynomolgus monkeys (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30218682/),,5,221784,DB00572,Atropine
,4032241,Maximum heart rates,"Maximum heart rates of 192 and 217% of the control values were observed at the lower and higher dose levels, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),%,192,224156,DB00572,Atropine
,4032241,Maximum heart rates,"Maximum heart rates of 192 and 217% of the control values were observed at the lower and higher dose levels, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),%,217,224157,DB00572,Atropine
,4032241,Minimum saliva flows,"Minimum saliva flows of 8 and 3% of the control values were measured after the lower and higher doses of atropine, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),%,8,224158,DB00572,Atropine
,4032241,Minimum saliva flows,"Minimum saliva flows of 8 and 3% of the control values were measured after the lower and higher doses of atropine, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),%,3,224159,DB00572,Atropine
,4032241,time durations,"The time durations of the positive chronotropic effect of the drug were 170 and 250 min at the lower and higher dose levels, respectively; the corresponding values for the length of the antisialogogue effect of the drug were 230 and 340 min, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),min,170,224160,DB00572,Atropine
,4032241,time durations,"The time durations of the positive chronotropic effect of the drug were 170 and 250 min at the lower and higher dose levels, respectively; the corresponding values for the length of the antisialogogue effect of the drug were 230 and 340 min, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),min,250,224161,DB00572,Atropine
,4032241,time durations,"The time durations of the positive chronotropic effect of the drug were 170 and 250 min at the lower and higher dose levels, respectively; the corresponding values for the length of the antisialogogue effect of the drug were 230 and 340 min, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),min,230,224162,DB00572,Atropine
,4032241,time durations,"The time durations of the positive chronotropic effect of the drug were 170 and 250 min at the lower and higher dose levels, respectively; the corresponding values for the length of the antisialogogue effect of the drug were 230 and 340 min, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),min,340,224163,DB00572,Atropine
,4032241,length of,"The time durations of the positive chronotropic effect of the drug were 170 and 250 min at the lower and higher dose levels, respectively; the corresponding values for the length of the antisialogogue effect of the drug were 230 and 340 min, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),min,230,224164,DB00572,Atropine
,4032241,length of,"The time durations of the positive chronotropic effect of the drug were 170 and 250 min at the lower and higher dose levels, respectively; the corresponding values for the length of the antisialogogue effect of the drug were 230 and 340 min, respectively.",Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032241/),min,340,224165,DB00572,Atropine
,4025866,concentrations,"Mean plasma fentanyl concentrations were 25.4, 12.7, and 7.9 ng/ml at 5, 15, and 30 min postbolus, respectively, with an elimination phase half-life of 35.8 min.",Cardiovascular and pharmacodynamic effects of high-dose fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025866/),[ng] / [ml],25.4,225103,DB00572,Atropine
,4025866,concentrations,"Mean plasma fentanyl concentrations were 25.4, 12.7, and 7.9 ng/ml at 5, 15, and 30 min postbolus, respectively, with an elimination phase half-life of 35.8 min.",Cardiovascular and pharmacodynamic effects of high-dose fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025866/),[ng] / [ml],12.7,225104,DB00572,Atropine
,4025866,concentrations,"Mean plasma fentanyl concentrations were 25.4, 12.7, and 7.9 ng/ml at 5, 15, and 30 min postbolus, respectively, with an elimination phase half-life of 35.8 min.",Cardiovascular and pharmacodynamic effects of high-dose fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025866/),[ng] / [ml],7.9,225105,DB00572,Atropine
,4025866,elimination phase half-life,"Mean plasma fentanyl concentrations were 25.4, 12.7, and 7.9 ng/ml at 5, 15, and 30 min postbolus, respectively, with an elimination phase half-life of 35.8 min.",Cardiovascular and pharmacodynamic effects of high-dose fentanyl in newborn piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025866/),min,35.8,225106,DB00572,Atropine
,134731,half-life,Subsequent elimination from the blood occurs with a half-life of 7h (rat) and 10 (dog).,[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),h,7,231334,DB00572,Atropine
,134731,half-life,Subsequent elimination from the blood occurs with a half-life of 7h (rat) and 10 (dog).,[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),,10,231335,DB00572,Atropine
,134731,half-life of elimination,The half-life of elimination following i.v. administration is 1.9 h (rat) and 3.4 h (dog).,[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),h,1.9,231336,DB00572,Atropine
,134731,half-life of elimination,The half-life of elimination following i.v. administration is 1.9 h (rat) and 3.4 h (dog).,[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),h,3.4,231337,DB00572,Atropine
,134731,renal excretion,In the same species renal excretion is 5.5% following oral administration and 58% following i.v. administration.,[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),%,5.5,231338,DB00572,Atropine
,134731,renal excretion,In the same species renal excretion is 5.5% following oral administration and 58% following i.v. administration.,[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),%,58,231339,DB00572,Atropine
,134731,Renal excretion,"Renal excretion in the dog, on the other hand, averaged 28% following oral and 55% following i.v. dosing, respectively.",[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),%,28,231340,DB00572,Atropine
,134731,Renal excretion,"Renal excretion in the dog, on the other hand, averaged 28% following oral and 55% following i.v. dosing, respectively.",[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),%,55,231341,DB00572,Atropine
,134731,absorption,"On the basis of a comparison of the areas under the blood level curves and also from the renal excretion following oral and i.v. dosing, i.e. disregarding absorption by gastrointestinal tissue, absorption was calculated as being 12% in the rat and 38% in the dog.",[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),%,12,231342,DB00572,Atropine
,134731,absorption,"On the basis of a comparison of the areas under the blood level curves and also from the renal excretion following oral and i.v. dosing, i.e. disregarding absorption by gastrointestinal tissue, absorption was calculated as being 12% in the rat and 38% in the dog.",[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),%,38,231343,DB00572,Atropine
,134731,Absorption,Absorption in the rat after 1--3 h was calculated at 17--35% including the gastrointestinal tissue.,[Studies on the pharmacokinetics and biotransformation of ipratropium bromide in the rat and dog]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/134731/),%,17,231344,DB00572,Atropine
,2228327,tmax,"The absorption rate and the elimination rate of dl-hyoscyamine and l-hyoscyamine were comparable (tmax = 8.40 vs 8.67 min, t1/2el = 2.95 vs 2.43 h, dose 0.02 mg/kg) but the mean maximum plasma concentration of dl-hyoscyamine was 2.9 times and the mean AUC value 6.0 times higher than that of l-hyoscyamine which indicates a kinetic difference between the enantiomers.",Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2228327/),min,8.40,235847,DB00572,Atropine
,2228327,tmax,"The absorption rate and the elimination rate of dl-hyoscyamine and l-hyoscyamine were comparable (tmax = 8.40 vs 8.67 min, t1/2el = 2.95 vs 2.43 h, dose 0.02 mg/kg) but the mean maximum plasma concentration of dl-hyoscyamine was 2.9 times and the mean AUC value 6.0 times higher than that of l-hyoscyamine which indicates a kinetic difference between the enantiomers.",Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2228327/),min,8.67,235848,DB00572,Atropine
,2228327,t1/2el,"The absorption rate and the elimination rate of dl-hyoscyamine and l-hyoscyamine were comparable (tmax = 8.40 vs 8.67 min, t1/2el = 2.95 vs 2.43 h, dose 0.02 mg/kg) but the mean maximum plasma concentration of dl-hyoscyamine was 2.9 times and the mean AUC value 6.0 times higher than that of l-hyoscyamine which indicates a kinetic difference between the enantiomers.",Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2228327/),h,2.95,235849,DB00572,Atropine
,2228327,t1/2el,"The absorption rate and the elimination rate of dl-hyoscyamine and l-hyoscyamine were comparable (tmax = 8.40 vs 8.67 min, t1/2el = 2.95 vs 2.43 h, dose 0.02 mg/kg) but the mean maximum plasma concentration of dl-hyoscyamine was 2.9 times and the mean AUC value 6.0 times higher than that of l-hyoscyamine which indicates a kinetic difference between the enantiomers.",Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2228327/),h,2.43,235850,DB00572,Atropine
,6824149,recovery times,"The basic dose schedule provided adequate surgical anaesthesia for 76% of patients (although dose adjustments were used in the remainder), with recovery times of 10 minutes or less in 57% of patients.",Total intravenous anaesthesia with etomidate-fentanyl. Use in general and gynaecological surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824149/),min,10,238660,DB00572,Atropine
,8166606,maximum levels,"Whereas the relatively nontoxic C(+/-)P(+)-isomers were not detected in blood, the highly toxic C(+/-)P(-)-isomers appeared within 1 min in the general circulation and reached maximum levels of 10-15 ng/ml blood within a period of ca. 7 min.",Toxicokinetics of soman stereoisomers after subcutaneous administration to atropinized guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166606/),[ng] / [blood·ml],10-15,239208,DB00572,Atropine
,8166606,systemic availability,A comparison with the toxicokinetics of the same isomers upon intravenous administration of the same dose shows that the systemic availability upon subcutaneous administration is in the range of 74-83%.,Toxicokinetics of soman stereoisomers after subcutaneous administration to atropinized guinea pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166606/),%,74-83,239209,DB00572,Atropine
,1783998,maximum serum concentration,The average maximum serum concentration (50 ng/mL) was reached in 29 min.,Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ng] / [ml],50,240801,DB00572,Atropine
,1783998,volume of distribution,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[l] / [kg],1.5,240802,DB00572,Atropine
,1783998,systemic clearance,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[l] / [kg],1.5,240803,DB00572,Atropine
,1783998,systemic clearance,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ml] / [kg·min],19.4,240804,DB00572,Atropine
,1783998,maximum concentration,"The percentage of diazepam unbound to serum proteins was 4.6% and, therefore, the maximum concentration of free diazepam was 2.3 ng/mL.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ng] / [ml],2.3,240805,DB00572,Atropine
,10459593,maximal atropine concentration (Cmax),"Both routes of atropine administration differed significantly in three measures: the maximal atropine concentration (Cmax) was significantly higher with the endobronchial administration 40.0 +/- 7.8 ng/ml compared to 23.9 +/- 5 ng/ml endotracheally (P = 0.008); atropine's elimination (t1/2beta) half-life was significantly longer with the endobronchial route (39.3 +/- 5.2 min vs. 28.0 +/- 7.9 min; P = 0.05); Endobronchial administration resulted in an increase of 16% in heart rate, beginning immediately after drug delivery and peaking after 5 min.",Atropine pharmacokinetics and pharmacodynamics following endotracheal versus endobronchial administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10459593/),[ng] / [ml],40.0,244997,DB00572,Atropine
,10459593,maximal atropine concentration (Cmax),"Both routes of atropine administration differed significantly in three measures: the maximal atropine concentration (Cmax) was significantly higher with the endobronchial administration 40.0 +/- 7.8 ng/ml compared to 23.9 +/- 5 ng/ml endotracheally (P = 0.008); atropine's elimination (t1/2beta) half-life was significantly longer with the endobronchial route (39.3 +/- 5.2 min vs. 28.0 +/- 7.9 min; P = 0.05); Endobronchial administration resulted in an increase of 16% in heart rate, beginning immediately after drug delivery and peaking after 5 min.",Atropine pharmacokinetics and pharmacodynamics following endotracheal versus endobronchial administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10459593/),[ng] / [ml],23.9,244998,DB00572,Atropine
,10459593,elimination (t1/2beta) half-life,"Both routes of atropine administration differed significantly in three measures: the maximal atropine concentration (Cmax) was significantly higher with the endobronchial administration 40.0 +/- 7.8 ng/ml compared to 23.9 +/- 5 ng/ml endotracheally (P = 0.008); atropine's elimination (t1/2beta) half-life was significantly longer with the endobronchial route (39.3 +/- 5.2 min vs. 28.0 +/- 7.9 min; P = 0.05); Endobronchial administration resulted in an increase of 16% in heart rate, beginning immediately after drug delivery and peaking after 5 min.",Atropine pharmacokinetics and pharmacodynamics following endotracheal versus endobronchial administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10459593/),min,39.3,244999,DB00572,Atropine
,10459593,elimination (t1/2beta) half-life,"Both routes of atropine administration differed significantly in three measures: the maximal atropine concentration (Cmax) was significantly higher with the endobronchial administration 40.0 +/- 7.8 ng/ml compared to 23.9 +/- 5 ng/ml endotracheally (P = 0.008); atropine's elimination (t1/2beta) half-life was significantly longer with the endobronchial route (39.3 +/- 5.2 min vs. 28.0 +/- 7.9 min; P = 0.05); Endobronchial administration resulted in an increase of 16% in heart rate, beginning immediately after drug delivery and peaking after 5 min.",Atropine pharmacokinetics and pharmacodynamics following endotracheal versus endobronchial administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10459593/),min,28.0,245000,DB00572,Atropine
,1542141,maximal plasma concentration,The maximal plasma concentration of oxaflozane was 63 ng/mL.,Oxaflozane overdose in a child. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542141/),[ng] / [ml],63,245954,DB00572,Atropine
,1542141,elimination half-life,The elimination half-life for N-dealkyloxaflozane was 4.8 h.,Oxaflozane overdose in a child. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542141/),h,4.8,245955,DB00572,Atropine
,8852700,IC50,"At 200 pmol/l [3H]NMS, IC50 was 1.4 +/- 0.1 x 10(-9) M atropine (CV = 8.1%).",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),M,1.4,247909,DB00572,Atropine
,8852700,absorption half-time,The atropine absorption half-time (7 min) was not affected either by the autoinjector type or by the combination with oximes.,Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),min,7,247910,DB00572,Atropine
,8852700,Maximal plasma concentration,"Maximal plasma concentration was 33 ng ml-1, elimination half-life 52 min, Vapp 3.2 l kg-1 and Clpl 44 ml min-1 kg-1.",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),[ng] / [ml],33,247911,DB00572,Atropine
,8852700,elimination half-life,"Maximal plasma concentration was 33 ng ml-1, elimination half-life 52 min, Vapp 3.2 l kg-1 and Clpl 44 ml min-1 kg-1.",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),min,52,247912,DB00572,Atropine
,8852700,Vapp,"Maximal plasma concentration was 33 ng ml-1, elimination half-life 52 min, Vapp 3.2 l kg-1 and Clpl 44 ml min-1 kg-1.",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),[l] / [kg],3.2,247913,DB00572,Atropine
,8852700,Clpl,"Maximal plasma concentration was 33 ng ml-1, elimination half-life 52 min, Vapp 3.2 l kg-1 and Clpl 44 ml min-1 kg-1.",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),[ml] / [kg·min],44,247914,DB00572,Atropine
,7174856,half-life,The average half-life of atropine was 4.125 hours.,Plasma pharmacokinetics of intravenously administered atropine in normal human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174856/),h,4.125,257448,DB00572,Atropine
,1293924,measurable lowest concentration,The measurable lowest concentration was 10 ng/ml plasma (S/N = 3:1).,[Studies on the determination of plasma level and pharmacokinetic parameters of anisodamine by micellar liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1293924/),[ng] / [ml·plasma],10,259483,DB00572,Atropine
,1293924,S/N,The measurable lowest concentration was 10 ng/ml plasma (S/N = 3:1).,[Studies on the determination of plasma level and pharmacokinetic parameters of anisodamine by micellar liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1293924/),,3:,259484,DB00572,Atropine
,1293924,S/N,The measurable lowest concentration was 10 ng/ml plasma (S/N = 3:1).,[Studies on the determination of plasma level and pharmacokinetic parameters of anisodamine by micellar liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1293924/),,1,259485,DB00572,Atropine
,16175141,releasing rate,The patch releases 0.5 mg alkaloid over a period of 3 days (releasing rate 5 microg/h).,Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),[μg] / [h],5,263383,DB00572,Atropine
,16175141,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) of approximately 100 pg/mL (range 11-240 pg/mL) of the alkaloid are reached after about 8 hours and achieve steady state.,Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),[pg] / [ml],100,263384,DB00572,Atropine
,16175141,tmax,"When scopolamine was administered together with 150 mL grapefruit juice, the alkaloid concentrations continued to increase, resulting in an evident prolongation of tmax (59.5 +/- 25.0 minutes; P < 0.001).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),min,59.5,263385,DB00572,Atropine
,16175141,absolute bioavailabilities,"Consequently, the related absolute bioavailabilities (range 6% to 37%) were significantly higher than the corresponding values of the drug orally administered together with water (range 3% to 27%).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),%,6,263386,DB00572,Atropine
,16175141,absolute bioavailabilities,"Consequently, the related absolute bioavailabilities (range 6% to 37%) were significantly higher than the corresponding values of the drug orally administered together with water (range 3% to 27%).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),%,37,263387,DB00572,Atropine
,16175141,absolute bioavailabilities,"Consequently, the related absolute bioavailabilities (range 6% to 37%) were significantly higher than the corresponding values of the drug orally administered together with water (range 3% to 27%).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),%,3,263388,DB00572,Atropine
,16175141,absolute bioavailabilities,"Consequently, the related absolute bioavailabilities (range 6% to 37%) were significantly higher than the corresponding values of the drug orally administered together with water (range 3% to 27%).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),%,27,263389,DB00572,Atropine
,8067894,plasma half-lives,"The plasma half-lives of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime amounted to 67, 63, 27, 55 and 179 min, respectively.","Comparison of the therapeutic effects and pharmacokinetics of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067894/),min,67,271060,DB00572,Atropine
,8067894,plasma half-lives,"The plasma half-lives of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime amounted to 67, 63, 27, 55 and 179 min, respectively.","Comparison of the therapeutic effects and pharmacokinetics of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067894/),min,63,271061,DB00572,Atropine
,8067894,plasma half-lives,"The plasma half-lives of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime amounted to 67, 63, 27, 55 and 179 min, respectively.","Comparison of the therapeutic effects and pharmacokinetics of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067894/),min,27,271062,DB00572,Atropine
,8067894,plasma half-lives,"The plasma half-lives of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime amounted to 67, 63, 27, 55 and 179 min, respectively.","Comparison of the therapeutic effects and pharmacokinetics of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067894/),min,55,271063,DB00572,Atropine
,8067894,plasma half-lives,"The plasma half-lives of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime amounted to 67, 63, 27, 55 and 179 min, respectively.","Comparison of the therapeutic effects and pharmacokinetics of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067894/),min,179,271064,DB00572,Atropine
